≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Cystic disease of liver

Endpoint Browser PheWeb

Q17_CYSTIC_DISEASE_OF_LIVER

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — Q44.6
  • Cause of death: ICD-10 — Q44.6

2 out of 7 registries used, show all original rules.

255

4. Check minimum number of events

None

255

5. Include endpoints

None

255

6. Filter based on genotype QC (FinnGen only)

248

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Similar endpoints

↥

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 248 178 70
Unadjusted period prevalence (%) 0.05 0.06 0.03
Median age at first event (years) 57.23 55.23 62.30

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
255
Matched controls
2550
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Q44.6
ICD-10 Finland
Cystic disease of liver
+∞
307.7
255
*
K76.80
ICD-10 Finland
Hepatic cyst
295.2
110.2
105
6
127
Kela drug reimbursment
Transplant complication
43.0
74.6
46
13
Q61.2
ICD-10 Finland
Polycystic kidney, autosomal dominant
863.0
69.5
65
*
Q61.3
ICD-10 Finland
Polycystic kidney, unspecified
248.8
58.7
58
*
L04AA06
ATC
mycophenolic acid; systemic
26.3
58.2
42
19
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
25.4
53.5
39
18
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
7.5
51.3
98
196
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
18.3
41.7
35
22
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
7.0
40.1
74
140
JJ5KT
NOMESCO Finland
Sclerotherapy of liver cyst
+∞
36.3
34
*
JN3AD
NOMESCO Finland
Abdominal CT examination
5.8
35.8
85
203
JJA31
NOMESCO Finland
Laparoscopic marsupialisation of cyst of liver
+∞
35.2
33
*
A11CC03
ATC
alfacalcidol; systemic
15.1
34.6
32
24
Z94.0
ICD-10 Finland
Kidney transplant status
80.6
31.8
35
5
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
7.6
28.3
44
68
L04AD02
ATC
tacrolimus; systemic
60.6
27.9
32
6
JN3BD
NOMESCO Finland
Extensive abdominal CT
5.4
27.1
64
149
Z94.4
ICD-10 Finland
Liver transplant status
78.1
25.4
28
*
TK800
NOMESCO Finland
Hemodialysis
23.1
25.2
36
18
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
3.7
23.7
149
700
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
72.0
23.3
26
*
JJC00
NOMESCO Finland
Allogenic transplantation of liver
92.1
23.1
25
*
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
39.1
22.6
28
8
Z49.1
ICD-10 Finland
Extracorporeal dialysis
39.4
20.2
25
7
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
30.6
19.1
25
9
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.3
19.0
119
540
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
5.7
18.2
37
74
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
102.3
17.8
19
*
JJ1AT
NOMESCO Finland
Puncture of lesion of liver with ultrasound guidance
192.8
17.7
18
*
JJ9AE
NOMESCO Finland
Ultrasound examination of liver transplant
192.8
17.7
18
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
5.5
17.7
37
76
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
14.0
17.7
30
24
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
34.2
17.3
22
7
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
68.1
17.0
19
*
KA9AE
NOMESCO Finland
Ultrasound examination transplanted kidney
181.4
16.7
17
*
H02AB04
ATC
methylprednisolone; systemic
3.5
15.4
65
228
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.9
15.1
162
954
B03XA02
ATC
darbepoetin alfa; parenteral
14.4
15.1
25
19
Z49.0
ICD-10 Finland
Preparatory care for dialysis
34.0
15.0
19
6
A12AA04
ATC
calcium carbonate; oral
18.4
14.6
22
13
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.6
14.1
55
182
V03AE02
ATC
sevelamer; oral
56.6
14.0
16
*
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
5.1
13.7
31
68
N18.8
ICD-10 Finland
Other chronic renal failure
13.3
12.9
22
18
7531A
ICD-9 Finland
Congenital anomalies of urinary system, Cystic kidney disease
+∞
12.6
12
*
L04AD01
ATC
ciclosporin; systemic
11.9
12.3
22
20
205
Kela drug reimbursment
Chronic hypertension
2.7
12.3
91
433
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
10.1
12.3
24
26
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
6.1
12.2
22
39
R10.1
ICD-10 Finland
Pain localized to upper abdomen
2.8
12.0
79
353
JJ5AT, ,
NOMESCO Finland
125.4
11.5
12
*
WX402
NOMESCO Finland
General anaesthesia
2.7
11.4
84
396
N18.0
ICD-10 Finland
End-stage renal disease
36.9
11.4
14
*
N02AX02
ATC
tramadol; systemic, rectal
2.5
11.3
140
843
UJF30
NOMESCO Finland
Ileoscopy through colon
3.4
11.1
46
157
C03CA01
ATC
furosemide; systemic
2.5
10.7
101
535
C08CA02
ATC
felodipine; oral
3.7
10.6
37
113
Q61.99
ICD-10 Finland
Cystic kidney disease, unspecified
+∞
10.5
10
*
JA3AT
NOMESCO Finland
Cathetrisation of abdominal cavity with ultrasound guidance
15.4
10.1
16
11
JN3DE
NOMESCO Finland
Abdominal extensive ultrasoudn examination with blood flow measurements after transplantation
41.8
10.1
12
*
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
7.9
9.9
22
30
V03AE01
ATC
polystyrene sulfonate; oral
21.1
9.9
14
7
J01MA02
ATC
ciprofloxacin; systemic
2.3
9.6
119
702
KAC00
NOMESCO Finland
Nephrectomy
103.7
9.5
10
*
320
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
22.7
9.4
13
6
N18.5
ICD-10 Finland
Chronic kidney disease, stage 5
22.7
9.4
13
6
Q61.1
ICD-10 Finland
Polycystic kidney, autosomal recessive
+∞
9.4
9
*
K42.9
ICD-10 Finland
Umbilical hernia without obstruction or gangrene
4.3
9.0
24
60
B03XA03
ATC
methoxy polyethylene glycol-epoetin beta; parenteral
25.1
9.0
12
5
V03AE03
ATC
lanthanum carbonate; oral
28.6
8.6
11
*
KA1AE
NOMESCO Finland
Kidney ultrasound examination
8.3
8.5
18
23
7516D
ICD-9 Finland
Other congenital anomalies of digestive system, Anomalies of gallbladder, bile ducts and liver[HEPAR POLYCYSTICUM]
+∞
8.4
8
*
R50.9
ICD-10 Finland
Fever, unspecified
2.6
8.2
53
231
TPH07
NOMESCO Finland
Cathetrisation of artery
2.9
8.2
43
168
KBV00
NOMESCO Finland
Insertion of stent into ureter
34.5
8.1
10
*
ZXE50
NOMESCO Finland
More than nine and less than 12 hours
11.3
7.9
14
13
PBL09
NOMESCO Finland
Construction of arteriovenous fistula from brachial artery
46.4
7.8
9
*
C02AC05
ATC
moxonidine; oral
4.3
7.7
20
49
R4110
NOMESCO Finland
Physiotherapy
2.2
7.5
91
521
PG5RT
NOMESCO Finland
PTA of arterio-venous shunt for dialysis
82.4
7.5
8
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.8
7.4
39
152
JAF30
NOMESCO Finland
Repair of umbilical hernia using prosthetic material
11.3
7.4
13
12
Q61.0
ICD-10 Finland
Congenital single renal cyst
+∞
7.3
7
*
JJA30
NOMESCO Finland
Marsupialisation of cyst of liver
+∞
7.3
7
*
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
4.2
7.3
20
51
WX408
NOMESCO Finland
General anesthesy, balanced
2.2
7.3
84
471
3AC01, ,
NOMESCO Finland
16.3
7.3
11
7
Z2446
NOMESCO Finland
Social worker
3.5
7.2
26
81
C07AG02
ATC
carvedilol; oral
3.5
7.2
26
81
UJF32
NOMESCO Finland
Coloscopy
2.1
7.2
87
497
JN4AD
NOMESCO Finland
Body CT examination
2.6
7.1
44
187
137
Kela drug reimbursment
Uraemia requiring dialysis
14.3
7.0
11
8
J01MA12
ATC
levofloxacin; systemic
2.3
6.9
60
298
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
4.3
6.9
18
44
RD210, ,
NOMESCO Finland
9.7
6.9
13
14
Z49.2
ICD-10 Finland
Other dialysis
17.3
6.8
10
6
XX6KT
NOMESCO Finland
Other sclerotherapy
41.2
6.8
8
*
JN1BD
NOMESCO Finland
Extensive CT examination of upper part of abdomen
23.2
6.7
9
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.4
6.5
51
242
Z94.9
ICD-10 Finland
Transplanted organ and tissue status, unspecified
71.6
6.5
7
*
JL5BG
NOMESCO Finland
MRI examinaiton of bile and pancreas ducts with high intesity magnet
6.2
6.4
16
27
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.3
6.4
54
265
B03XA01
ATC
erythropoietin; parenteral
18.6
6.3
9
5
K43.9
ICD-10 Finland
Other and unspecified ventral hernia without obstruction or gangrene
3.5
6.3
22
67
75310
ICD-8 Finland
Congenital anomalies of urinary system, Ren polycysticus bilateralis
+∞
6.3
6
*
PG5DE
NOMESCO Finland
Ultrasound examination of injection gate to artery or vein with Doppler method
27.4
6.3
8
*
A02BC05
ATC
esomeprazole; systemic
1.9
6.2
120
801
K83.0
ICD-10 Finland
Cholangitis
10.4
6.1
11
11

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Nephrology
39 [38004479]
2.9e+00
3.0e+00
2.9e+00
—
3.0e+00
3.2e+00
2.7e+00
cases:11.42%
controls:0.67%
cases:10.24%
controls:0.55%
cases:4.72%
controls:0.28%
—
—
cases:5.98%
controls:0.32%
cases:12.81%
controls:0.57%
cases:15.87%
controls:1.19%
29
17
225
2523
26
14
228
2526
12
7
242
2533
—
15
8
236
2527
31
14
211
2438
33
25
175
2073
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
1.5e+00
2.4e+00
3.2e+00
—
2.9e+00
2.7e+00
2.2e+00
cases:4.72%
controls:1.10%
cases:7.09%
controls:0.67%
cases:4.72%
controls:0.20%
—
—
cases:3.98%
controls:0.24%
cases:9.50%
controls:0.69%
cases:13.94%
controls:1.81%
12
28
242
2512
18
17
236
2523
12
5
242
2535
—
10
6
241
2529
23
17
219
2435
29
38
179
2060
mycophenolic acid; oral, parenteral
L04AA06 [21603896]
2.8e+00
3.1e+00
—
—
—
3.1e+00
3.7e+00
cases:3.94%
controls:0.24%
cases:4.33%
controls:0.20%
—
—
—
—
—
—
cases:4.55%
controls:0.20%
cases:8.65%
controls:0.24%
10
6
244
2534
11
5
243
2535
—
—
—
11
5
231
2447
18
5
190
2093
Upper gastrointestinal surgery
106 [44777669]
8.1e-01
1.5e+00
2.4e+00
1.0e+50
3.5e+00
2.5e+00
1.7e+00
cases:18.11%
controls:8.94%
cases:13.78%
controls:3.43%
cases:4.33%
controls:0.39%
cases:34.65%
controls:0.00%
cases:8.76%
controls:0.28%
cases:25.62%
controls:2.81%
cases:37.98%
controls:9.72%
46
227
208
2313
35
87
219
2453
11
10
243
2530
88
0
166
2540
22
7
229
2528
62
69
180
2383
79
204
129
1894
Gastroenterology
10 [38004455]
1.1e+00
1.5e+00
2.7e+00
1.0e+50
2.6e+00
2.5e+00
1.6e+00
cases:13.78%
controls:5.20%
cases:11.02%
controls:2.68%
cases:4.33%
controls:0.31%
cases:20.47%
controls:0.00%
cases:5.18%
controls:0.39%
cases:18.60%
controls:1.88%
cases:25.00%
controls:6.39%
35
132
219
2408
28
68
226
2472
11
8
243
2532
52
0
202
2540
13
10
238
2525
45
46
197
2406
52
134
156
1964
alfacalcidol; oral, parenteral
A11CC03 [21600818]
3.2e+00
2.5e+00
—
—
—
3.0e+00
3.1e+00
cases:4.72%
controls:0.20%
cases:2.76%
controls:0.24%
—
—
—
—
—
—
cases:4.55%
controls:0.24%
cases:5.77%
controls:0.29%
12
5
242
2535
7
6
247
2534
—
—
—
11
6
231
2446
12
6
196
2092
Abdominal ultrasound examination
JN3AE [2001305555]
2.2e+00
3.2e+00
—
1.0e+50
—
3.3e+00
2.6e+00
cases:8.66%
controls:1.02%
cases:4.72%
controls:0.20%
—
—
cases:2.76%
controls:0.00%
—
—
cases:5.37%
controls:0.20%
cases:12.02%
controls:1.00%
22
26
232
2514
12
5
242
2535
—
7
0
247
2540
—
13
5
229
2447
25
21
183
2077
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
7.0e-01
1.8e+00
3.5e+00
—
1.8e+00
1.8e+00
1.4e+00
cases:14.57%
controls:7.80%
cases:19.29%
controls:3.86%
cases:14.17%
controls:0.47%
—
—
cases:4.78%
controls:0.79%
cases:20.66%
controls:4.16%
cases:30.29%
controls:9.58%
37
198
217
2342
49
98
205
2442
36
12
218
2528
—
12
20
239
2515
50
102
192
2350
63
201
145
1897
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
3.9e-01
1.3e+00
2.3e+00
3.5e+00
1.6e+00
1.1e+00
9.2e-01
cases:24.02%
controls:17.68%
cases:29.53%
controls:10.71%
cases:18.90%
controls:2.28%
cases:5.91%
controls:0.20%
cases:8.37%
controls:1.81%
cases:27.27%
controls:10.85%
cases:41.35%
controls:21.93%
61
449
193
2091
75
272
179
2268
48
58
206
2482
15
5
239
2535
21
46
230
2489
66
266
176
2186
86
460
122
1638
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
1.5e+00
2.1e+00
2.7e+00
—
—
2.4e+00
1.9e+00
cases:8.27%
controls:1.97%
cases:8.66%
controls:1.14%
cases:3.54%
controls:0.24%
—
—
—
—
cases:9.92%
controls:1.02%
cases:16.35%
controls:2.81%
21
50
233
2490
22
29
232
2511
9
6
245
2534
—
—
24
25
218
2427
34
59
174
2039
Cystatin C [Mass/volume] in Serum or Plasma
33863-2 [3030366]
2.0e+00
2.5e+00
—
—
—
2.9e+00
2.9e+00
cases:3.15%
controls:0.43%
cases:2.76%
controls:0.24%
—
—
—
—
—
—
cases:4.96%
controls:0.29%
cases:8.17%
controls:0.48%
8
11
246
2529
7
6
247
2534
—
—
—
12
7
230
2445
17
10
191
2088
Outpatient Visit
OP [9202]
4.1e-01
6.8e-01
9.3e-01
4.9e+00
1.0e+00
1.2e+00
9.3e-01
cases:77.17%
controls:69.21%
cases:63.78%
controls:47.13%
cases:21.26%
controls:9.61%
cases:44.88%
controls:0.63%
cases:23.11%
controls:9.63%
cases:74.79%
controls:47.35%
cases:88.46%
controls:75.21%
196
1758
58
782
162
1197
92
1343
54
244
200
2296
114
16
140
2524
58
244
193
2291
181
1161
61
1291
184
1578
24
520
pH of Serum or Plasma
2753-2 [3018418]
9.6e-01
1.4e+00
1.9e+00
—
2.2e+00
1.7e+00
1.3e+00
cases:12.99%
controls:5.43%
cases:10.24%
controls:2.68%
cases:3.15%
controls:0.47%
—
—
cases:2.79%
controls:0.32%
cases:10.33%
controls:2.04%
cases:21.15%
controls:6.72%
33
138
221
2402
26
68
228
2472
8
12
246
2528
—
7
8
244
2527
25
50
217
2402
44
141
164
1957
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
6.0e-01
1.6e+00
3.0e+00
—
1.8e+00
1.7e+00
1.3e+00
cases:16.54%
controls:9.84%
cases:21.26%
controls:5.24%
cases:16.54%
controls:0.94%
—
—
cases:5.18%
controls:0.87%
cases:21.49%
controls:4.85%
cases:32.69%
controls:11.20%
42
250
212
2290
54
133
200
2407
42
24
212
2516
—
13
22
238
2513
52
119
190
2333
68
235
140
1863
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
7.0e-01
1.3e+00
2.1e+00
—
2.2e+00
1.5e+00
1.0e+00
cases:14.96%
controls:8.07%
cases:12.60%
controls:3.86%
cases:4.72%
controls:0.59%
—
—
cases:3.98%
controls:0.47%
cases:14.05%
controls:3.38%
cases:23.08%
controls:9.77%
38
205
216
2335
32
98
222
2442
12
15
242
2525
—
10
12
241
2523
34
83
208
2369
48
205
160
1893
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
8.5e-01
1.6e+00
—
1.0e+50
2.5e+00
2.0e+00
1.6e+00
cases:9.84%
controls:4.45%
cases:10.63%
controls:2.28%
—
—
cases:2.36%
controls:0.00%
cases:2.79%
controls:0.24%
cases:10.74%
controls:1.67%
cases:17.31%
controls:4.00%
25
113
229
2427
27
58
227
2482
—
6
0
248
2540
7
6
244
2529
26
41
216
2411
36
84
172
2014
Chronic kidney disease, unspecified
N18.9 [45553438]
1.8e+00
2.3e+00
—
—
—
2.3e+00
1.9e+00
cases:3.15%
controls:0.51%
cases:2.36%
controls:0.24%
—
—
—
—
—
—
cases:3.31%
controls:0.33%
cases:6.25%
controls:0.95%
8
13
246
2527
6
6
248
2534
—
—
—
8
8
234
2444
13
20
195
2078
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
7.0e-01
1.2e+00
2.1e+00
—
2.0e+00
1.5e+00
8.9e-01
cases:16.54%
controls:8.94%
cases:14.17%
controls:4.80%
cases:5.12%
controls:0.63%
—
—
cases:4.38%
controls:0.63%
cases:15.29%
controls:4.00%
cases:24.52%
controls:11.77%
42
227
212
2313
36
122
218
2418
13
16
241
2524
—
11
16
240
2519
37
98
205
2354
51
247
157
1851
calcium carbonate; oral
A12AA04 [21600863]
3.1e+00
—
—
—
—
2.5e+00
2.5e+00
cases:4.33%
controls:0.20%
—
—
—
—
—
—
—
—
cases:2.48%
controls:0.20%
cases:3.85%
controls:0.33%
11
5
243
2535
—
—
—
—
6
5
236
2447
8
7
200
2091
calcium carbonate
A02AC01 [21600065]
3.1e+00
—
—
—
—
2.5e+00
2.5e+00
cases:4.33%
controls:0.20%
—
—
—
—
—
—
—
—
cases:2.48%
controls:0.20%
cases:3.85%
controls:0.33%
11
5
243
2535
—
—
—
—
6
5
236
2447
8
7
200
2091
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
2.9e-01
9.2e-01
2.6e+00
—
2.4e+00
1.2e+00
8.4e-01
cases:14.17%
controls:11.02%
cases:11.42%
controls:4.88%
cases:6.69%
controls:0.55%
—
—
cases:4.38%
controls:0.39%
cases:14.88%
controls:4.98%
cases:25.96%
controls:13.20%
36
280
218
2260
29
124
225
2416
17
14
237
2526
—
11
10
240
2525
36
122
206
2330
54
277
154
1821
ciclosporin; oral, parenteral
L04AD01 [21603924]
2.5e+00
—
—
—
—
2.8e+00
2.6e+00
cases:2.76%
controls:0.24%
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.20%
cases:4.81%
controls:0.38%
7
6
247
2534
—
—
—
—
8
5
234
2447
10
8
198
2090
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
8.5e-01
1.5e+00
2.5e+00
—
2.0e+00
2.1e+00
1.7e+00
cases:5.51%
controls:2.44%
cases:6.69%
controls:1.61%
cases:2.36%
controls:0.20%
—
—
cases:1.99%
controls:0.28%
cases:7.02%
controls:0.90%
cases:14.42%
controls:2.86%
14
62
240
2478
17
41
237
2499
6
5
248
2535
—
5
7
246
2528
17
22
225
2430
30
60
178
2038
Cancer Ag 19-9 [Units/volume] in Serum or Plasma
24108-3 [3022914]
1.4e+00
2.2e+00
—
—
—
2.8e+00
2.8e+00
cases:2.36%
controls:0.59%
cases:3.15%
controls:0.35%
—
—
—
—
—
—
cases:4.96%
controls:0.33%
cases:8.17%
controls:0.52%
6
15
248
2525
8
9
246
2531
—
—
—
12
8
230
2444
17
11
191
2087
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
1.7e+00
2.2e+00
—
—
—
1.9e+00
1.9e+00
cases:5.91%
controls:1.14%
cases:6.30%
controls:0.75%
—
—
—
—
—
—
cases:6.20%
controls:0.94%
cases:11.06%
controls:1.86%
15
29
239
2511
16
19
238
2521
—
—
—
15
23
227
2429
23
39
185
2059
Ultrasound examination of upper part of abdomen
JN1AE [2001305517]
1.3e+00
2.5e+00
—
1.0e+50
—
2.9e+00
2.3e+00
cases:2.76%
controls:0.79%
cases:2.76%
controls:0.24%
—
—
cases:3.54%
controls:0.00%
—
—
cases:4.13%
controls:0.24%
cases:9.62%
controls:1.05%
7
20
247
2520
7
6
247
2534
—
9
0
245
2540
—
10
6
232
2446
20
22
188
2076
Abdominal CT examination
JN3AD [2001305554]
1.4e+00
2.3e+00
—
1.0e+50
—
2.3e+00
1.4e+00
cases:3.94%
controls:0.98%
cases:4.33%
controls:0.43%
—
—
cases:2.76%
controls:0.00%
—
—
cases:3.31%
controls:0.33%
cases:6.73%
controls:1.76%
10
25
244
2515
11
11
243
2529
—
7
0
247
2540
—
8
8
234
2444
14
37
194
2061
methylprednisolone; oral, parenteral
H02AB04 [21602732]
1.2e+00
2.6e+00
—
—
—
1.7e+00
1.9e+00
cases:6.30%
controls:1.89%
cases:5.51%
controls:0.43%
—
—
—
—
—
—
cases:4.13%
controls:0.77%
cases:9.13%
controls:1.53%
16
48
238
2492
14
11
240
2529
—
—
—
10
19
232
2433
19
32
189
2066
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
8.5e-01
2.3e+00
1.0e+50
—
—
2.9e+00
2.1e+00
cases:5.12%
controls:2.24%
cases:5.91%
controls:0.63%
cases:5.91%
controls:0.00%
—
—
—
—
cases:9.09%
controls:0.53%
cases:12.98%
controls:1.81%
13
57
241
2483
15
16
239
2524
15
0
239
2540
—
—
22
13
220
2439
27
38
181
2060
General Surgery
2 [38004447]
3.3e-01
1.2e+00
2.0e+00
—
1.9e+00
1.2e+00
8.6e-01
cases:24.41%
controls:18.82%
cases:16.93%
controls:5.55%
cases:4.72%
controls:0.67%
—
—
cases:6.77%
controls:1.07%
cases:16.53%
controls:5.67%
cases:31.73%
controls:16.44%
62
478
192
2062
43
141
211
2399
12
17
242
2523
—
17
27
234
2508
40
139
202
2313
66
345
142
1753
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
8.6e-02
6.6e-01
1.8e+00
2.9e+00
1.1e+00
5.9e-01
4.8e-01
cases:24.02%
controls:22.48%
cases:29.53%
controls:17.80%
cases:18.90%
controls:3.82%
cases:4.33%
controls:0.24%
cases:9.56%
controls:3.39%
cases:28.10%
controls:17.78%
cases:39.90%
controls:29.08%
61
571
193
1969
75
452
179
2088
48
97
206
2443
11
6
243
2534
24
86
227
2449
68
436
174
2016
83
610
125
1488
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
1.4e+00
2.6e+00
—
—
—
2.4e+00
2.1e+00
cases:2.36%
controls:0.59%
cases:3.15%
controls:0.24%
—
—
—
—
—
—
cases:5.37%
controls:0.53%
cases:10.10%
controls:1.38%
6
15
248
2525
8
6
246
2534
—
—
—
13
13
229
2439
21
29
187
2069
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
2.3e+00
—
—
—
—
2.5e+00
2.1e+00
cases:3.15%
controls:0.31%
—
—
—
—
—
—
—
—
cases:2.48%
controls:0.20%
cases:4.33%
controls:0.57%
8
8
246
2532
—
—
—
—
6
5
236
2447
9
12
199
2086
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
—
2.7e+00
—
—
—
2.3e+00
1.9e+00
—
—
cases:2.76%
controls:0.20%
—
—
—
—
—
—
cases:2.48%
controls:0.24%
cases:4.81%
controls:0.76%
—
7
5
247
2535
—
—
—
6
6
236
2446
10
16
198
2082
Internal Medicine
11 [38004456]
3.1e-01
1.3e+00
1.8e+00
—
1.5e+00
1.4e+00
9.3e-01
cases:26.77%
controls:21.18%
cases:21.65%
controls:7.28%
cases:5.91%
controls:1.06%
—
—
cases:5.58%
controls:1.30%
cases:23.97%
controls:7.10%
cases:37.02%
controls:18.83%
68
538
186
2002
55
185
199
2355
15
27
239
2513
—
14
33
237
2502
58
174
184
2278
77
395
131
1703
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
3.9e-01
1.3e+00
3.1e+00
—
1.4e+00
1.3e+00
1.0e+00
cases:9.45%
controls:6.61%
cases:9.45%
controls:2.64%
cases:6.69%
controls:0.31%
—
—
cases:1.99%
controls:0.51%
cases:10.33%
controls:3.02%
cases:20.19%
controls:8.29%
24
168
230
2372
24
67
230
2473
17
8
237
2532
—
5
13
246
2522
25
74
217
2378
42
174
166
1924
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
8.9e-01
2.5e+00
—
—
—
2.6e+00
1.5e+00
cases:3.94%
controls:1.65%
cases:5.51%
controls:0.47%
—
—
—
—
—
—
cases:4.96%
controls:0.37%
cases:7.69%
controls:1.86%
10
42
244
2498
14
12
240
2528
—
—
—
12
9
230
2443
16
39
192
2059
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
1.0e+00
1.6e+00
—
—
2.0e+00
2.2e+00
1.8e+00
cases:5.91%
controls:2.20%
cases:7.09%
controls:1.50%
—
—
—
—
cases:1.99%
controls:0.28%
cases:7.02%
controls:0.82%
cases:14.42%
controls:2.76%
15
56
239
2484
18
38
236
2502
—
—
5
7
246
2528
17
20
225
2432
30
58
178
2040
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
3.1e-01
1.2e+00
3.4e+00
—
1.2e+00
1.1e+00
9.4e-01
cases:18.11%
controls:13.98%
cases:18.50%
controls:6.57%
cases:11.02%
controls:0.39%
—
—
cases:3.59%
controls:1.10%
cases:16.94%
controls:6.53%
cases:34.62%
controls:17.11%
46
355
208
2185
47
167
207
2373
28
10
226
2530
—
9
28
242
2507
41
160
201
2292
72
359
136
1739
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
1.3e+00
2.2e+00
—
—
—
2.7e+00
1.7e+00
cases:2.36%
controls:0.63%
cases:3.15%
controls:0.35%
—
—
—
—
—
—
cases:2.89%
controls:0.20%
cases:4.81%
controls:0.91%
6
16
248
2524
8
9
246
2531
—
—
—
7
5
235
2447
10
19
198
2079
Gas panel - Venous blood
24339-4 [3000991]
1.2e+00
2.2e+00
—
—
—
2.3e+00
2.0e+00
cases:3.54%
controls:1.14%
cases:4.72%
controls:0.55%
—
—
—
—
—
—
cases:7.02%
controls:0.73%
cases:11.54%
controls:1.76%
9
29
245
2511
12
14
242
2526
—
—
—
17
18
225
2434
24
37
184
2061
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.2e-01
5.6e-01
1.8e+00
3.2e+00
9.6e-01
4.6e-01
3.9e-01
cases:34.65%
controls:31.97%
cases:38.19%
controls:26.18%
cases:25.20%
controls:5.47%
cases:5.51%
controls:0.24%
cases:11.95%
controls:4.93%
cases:35.95%
controls:26.14%
cases:51.44%
controls:41.85%
88
812
166
1728
97
665
157
1875
64
139
190
2401
14
6
240
2534
30
125
221
2410
87
641
155
1811
107
878
101
1220
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
1.1e+00
1.6e+00
—
—
—
1.8e+00
1.7e+00
cases:5.51%
controls:1.85%
cases:3.54%
controls:0.75%
—
—
—
—
—
—
cases:4.96%
controls:0.90%
cases:10.10%
controls:2.00%
14
47
240
2493
9
19
245
2521
—
—
—
12
22
230
2430
21
42
187
2056
Thorax X-ray examination
GD1AA [2001303617]
4.6e-01
1.6e+00
1.9e+00
1.0e+50
—
1.3e+00
1.4e+00
cases:12.60%
controls:8.31%
cases:9.06%
controls:2.05%
cases:2.76%
controls:0.43%
cases:2.36%
controls:0.00%
—
—
cases:9.50%
controls:2.69%
cases:24.04%
controls:7.48%
32
211
222
2329
23
52
231
2488
7
11
247
2529
6
0
248
2540
—
23
66
219
2386
50
157
158
1941
INR in Blood by Coagulation assay
34714-6 [3032080]
4.4e-01
1.1e+00
2.1e+00
—
1.2e+00
1.5e+00
1.4e+00
cases:13.39%
controls:9.02%
cases:12.99%
controls:4.69%
cases:12.20%
controls:1.65%
—
—
cases:4.78%
controls:1.54%
cases:19.42%
controls:5.14%
cases:28.85%
controls:9.15%
34
229
220
2311
33
119
221
2421
31
42
223
2498
—
12
39
239
2496
47
126
195
2326
60
192
148
1906
Platelets [#/volume] in Blood
26515-7 [3007461]
4.2e-02
4.8e-01
1.8e+00
2.8e+00
8.9e-01
4.0e-01
2.7e-01
cases:35.43%
controls:34.49%
cases:39.37%
controls:28.66%
cases:25.98%
controls:5.75%
cases:6.30%
controls:0.39%
cases:12.75%
controls:5.64%
cases:37.60%
controls:28.75%
cases:51.44%
controls:44.66%
90
876
164
1664
100
728
154
1812
66
146
188
2394
16
10
238
2530
32
143
219
2392
91
705
151
1747
107
937
101
1161
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
3.8e-02
4.8e-01
1.7e+00
2.8e+00
8.9e-01
4.1e-01
2.7e-01
cases:35.43%
controls:34.57%
cases:39.37%
controls:28.66%
cases:25.98%
controls:5.79%
cases:6.30%
controls:0.39%
cases:12.75%
controls:5.68%
cases:38.02%
controls:28.83%
cases:51.44%
controls:44.66%
90
878
164
1662
100
728
154
1812
66
147
188
2393
16
10
238
2530
32
144
219
2391
92
707
150
1745
107
937
101
1161
MCH [Entitic mass]
28539-5 [3035941]
4.2e-02
4.8e-01
1.7e+00
2.8e+00
8.9e-01
4.0e-01
2.8e-01
cases:35.43%
controls:34.49%
cases:39.37%
controls:28.66%
cases:25.98%
controls:5.79%
cases:6.30%
controls:0.39%
cases:12.75%
controls:5.68%
cases:37.60%
controls:28.79%
cases:51.44%
controls:44.52%
90
876
164
1664
100
728
154
1812
66
147
188
2393
16
10
238
2530
32
144
219
2391
91
706
151
1746
107
934
101
1164
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
3.8e-02
4.8e-01
1.7e+00
2.8e+00
8.9e-01
4.1e-01
2.7e-01
cases:35.43%
controls:34.57%
cases:39.37%
controls:28.70%
cases:25.98%
controls:5.79%
cases:6.30%
controls:0.39%
cases:12.75%
controls:5.68%
cases:38.02%
controls:28.83%
cases:51.44%
controls:44.66%
90
878
164
1662
100
729
154
1811
66
147
188
2393
16
10
238
2530
32
144
219
2391
92
707
150
1745
107
937
101
1161
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
3.5e-02
4.7e-01
1.7e+00
2.8e+00
8.9e-01
4.1e-01
2.7e-01
cases:35.43%
controls:34.65%
cases:39.37%
controls:28.78%
cases:25.98%
controls:5.79%
cases:6.30%
controls:0.39%
cases:12.75%
controls:5.68%
cases:38.02%
controls:28.96%
cases:51.44%
controls:44.71%
90
880
164
1660
100
731
154
1809
66
147
188
2393
16
10
238
2530
32
144
219
2391
92
710
150
1742
107
938
101
1160
Base excess in Venous blood by calculation
1927-3 [3002032]
9.4e-01
2.0e+00
—
—
—
2.2e+00
1.8e+00
cases:3.54%
controls:1.42%
cases:3.94%
controls:0.55%
—
—
—
—
—
—
cases:5.79%
controls:0.69%
cases:12.98%
controls:2.53%
9
36
245
2504
10
14
244
2526
—
—
—
14
17
228
2435
27
53
181
2045
Leukocytes [#/volume] in Blood
26464-8 [3010813]
3.8e-02
4.8e-01
1.7e+00
2.8e+00
8.8e-01
4.1e-01
2.7e-01
cases:35.43%
controls:34.57%
cases:39.37%
controls:28.70%
cases:25.98%
controls:5.87%
cases:6.30%
controls:0.39%
cases:12.75%
controls:5.72%
cases:38.02%
controls:28.92%
cases:51.44%
controls:44.61%
90
878
164
1662
100
729
154
1811
66
149
188
2391
16
10
238
2530
32
145
219
2390
92
709
150
1743
107
936
101
1162
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
3.8e-02
4.6e-01
1.7e+00
2.8e+00
8.9e-01
4.1e-01
2.8e-01
cases:35.43%
controls:34.57%
cases:38.98%
controls:28.74%
cases:25.98%
controls:5.87%
cases:6.30%
controls:0.39%
cases:12.75%
controls:5.68%
cases:38.02%
controls:28.83%
cases:51.44%
controls:44.57%
90
878
164
1662
99
730
155
1810
66
149
188
2391
16
10
238
2530
32
144
219
2391
92
707
150
1745
107
935
101
1163
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
—
2.2e+00
—
—
—
2.2e+00
1.4e+00
—
—
cases:2.76%
controls:0.31%
—
—
—
—
—
—
cases:2.89%
controls:0.33%
cases:5.77%
controls:1.48%
—
7
8
247
2532
—
—
—
7
8
235
2444
12
31
196
2067
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
5.5e-01
1.1e+00
2.9e+00
—
—
1.4e+00
1.5e+00
cases:2.76%
controls:1.61%
cases:3.94%
controls:1.30%
cases:4.72%
controls:0.28%
—
—
—
—
cases:4.55%
controls:1.18%
cases:8.17%
controls:2.00%
7
41
247
2499
10
33
244
2507
12
7
242
2533
—
—
11
29
231
2423
17
42
191
2056
Bacteria identified in Blood by Culture
600-7 [3023368]
9.1e-02
1.1e+00
2.3e+00
—
2.3e+00
1.1e+00
1.1e+00
cases:4.72%
controls:4.33%
cases:3.54%
controls:1.26%
cases:2.36%
controls:0.24%
—
—
cases:1.99%
controls:0.20%
cases:4.96%
controls:1.67%
cases:12.98%
controls:4.91%
12
110
242
2430
9
32
245
2508
6
6
248
2534
—
5
5
246
2530
12
41
230
2411
27
103
181
1995
Oxygen saturation in Arterial blood
2708-6 [3016502]
—
2.2e+00
—
—
—
2.1e+00
1.3e+00
—
—
cases:2.76%
controls:0.31%
—
—
—
—
—
—
cases:3.31%
controls:0.41%
cases:5.77%
controls:1.62%
—
7
8
247
2532
—
—
—
8
10
234
2442
12
34
196
2064
pH of Venous blood
2746-6 [3012544]
9.1e-01
1.8e+00
—
—
—
2.1e+00
1.7e+00
cases:3.54%
controls:1.46%
cases:3.94%
controls:0.67%
—
—
—
—
—
—
cases:5.79%
controls:0.77%
cases:12.98%
controls:2.72%
9
37
245
2503
10
17
244
2523
—
—
—
14
19
228
2433
27
57
181
2041
Physiotherapy
R4110 [2001310233]
9.7e-01
1.8e+00
—
—
—
1.5e+00
1.3e+00
cases:9.45%
controls:3.82%
cases:6.30%
controls:1.14%
—
—
—
—
—
—
cases:7.02%
controls:1.67%
cases:11.54%
controls:3.43%
24
97
230
2443
16
29
238
2511
—
—
—
17
41
225
2411
24
72
184
2026
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
9.1e-01
1.8e+00
—
—
—
2.1e+00
1.7e+00
cases:3.54%
controls:1.46%
cases:3.54%
controls:0.63%
—
—
—
—
—
—
cases:5.79%
controls:0.77%
cases:13.46%
controls:2.81%
9
37
245
2503
9
16
245
2524
—
—
—
14
19
228
2433
28
59
180
2039
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
1.2e+00
1.6e+00
-1.0e+50
—
—
1.4e+00
1.2e+00
cases:6.69%
controls:2.20%
cases:6.30%
controls:1.34%
cases:0.00%
controls:0.20%
—
—
—
—
cases:4.96%
controls:1.22%
cases:11.06%
controls:3.57%
17
56
237
2484
16
34
238
2506
0
5
254
2535
—
—
12
30
230
2422
23
75
185
2023
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
8.1e-02
8.5e-01
2.0e+00
—
1.3e+00
7.1e-01
5.6e-01
cases:28.35%
controls:26.73%
cases:31.89%
controls:16.61%
cases:18.11%
controls:3.03%
—
—
cases:10.36%
controls:3.00%
cases:27.69%
controls:15.78%
cases:45.19%
controls:32.13%
72
679
182
1861
81
422
173
2118
46
77
208
2463
—
26
76
225
2459
67
387
175
2065
94
674
114
1424
CBC panel - Blood by Automated count
58410-2 [40761511]
-1.9e-02
3.9e-01
1.9e+00
2.6e+00
9.5e-01
4.2e-01
2.5e-01
cases:29.13%
controls:29.53%
cases:25.20%
controls:18.54%
cases:17.72%
controls:3.23%
cases:3.54%
controls:0.28%
cases:7.57%
controls:3.08%
cases:24.79%
controls:17.74%
cases:40.87%
controls:34.94%
74
750
180
1790
64
471
190
2069
45
82
209
2458
9
7
245
2533
19
78
232
2457
60
435
182
2017
85
733
123
1365
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
8.0e-01
1.7e+00
—
—
—
1.5e+00
1.2e+00
cases:10.24%
controls:4.88%
cases:11.81%
controls:2.36%
—
—
—
—
—
—
cases:9.09%
controls:2.12%
cases:16.35%
controls:5.43%
26
124
228
2416
30
60
224
2480
—
—
—
22
52
220
2400
34
114
174
1984
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
8.6e-01
1.5e+00
—
—
2.0e+00
2.0e+00
1.8e+00
cases:5.91%
controls:2.60%
cases:7.09%
controls:1.73%
—
—
—
—
cases:1.99%
controls:0.28%
cases:7.02%
controls:1.06%
cases:15.87%
controls:3.00%
15
66
239
2474
18
44
236
2496
—
—
5
7
246
2528
17
26
225
2426
33
63
175
2035
Hemodialysis
TK800 [2001305768]
—
2.5e+00
—
—
—
2.8e+00
—
—
—
cases:3.15%
controls:0.28%
—
—
—
—
—
—
cases:3.72%
controls:0.24%
—
—
—
8
7
246
2533
—
—
—
9
6
233
2446
—
Base excess in Arterial blood by calculation
1925-7 [3003396]
4.5e-01
1.9e+00
—
—
—
2.0e+00
1.3e+00
cases:1.97%
controls:1.26%
cases:2.76%
controls:0.43%
—
—
—
—
—
—
cases:2.89%
controls:0.41%
cases:5.77%
controls:1.67%
5
32
249
2508
7
11
247
2529
—
—
—
7
10
235
2442
12
35
196
2063
Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
72493-0 [43055120]
2.0e+00
—
—
—
—
—
3.0e+00
cases:2.36%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
cases:8.65%
controls:0.48%
6
8
248
2532
—
—
—
—
—
18
10
190
2088
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
9.9e-01
1.5e+00
-1.0e+50
—
—
1.3e+00
1.2e+00
cases:6.30%
controls:2.44%
cases:6.30%
controls:1.46%
cases:0.00%
controls:0.24%
—
—
—
—
cases:5.37%
controls:1.51%
cases:11.54%
controls:3.91%
16
62
238
2478
16
37
238
2503
0
6
254
2534
—
—
13
37
229
2415
24
82
184
2016
Epstein Barr virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
43730-1 [3043849]
2.5e+00
1.0e+50
—
—
—
—
2.5e+00
cases:2.76%
controls:0.24%
cases:2.36%
controls:0.00%
—
—
—
—
—
—
—
—
cases:5.29%
controls:0.48%
7
6
247
2534
6
0
248
2540
—
—
—
—
11
10
197
2088
Outpatient Hospital
22 [8756]
4.4e-01
8.2e-01
—
1.0e+50
1.7e+00
1.5e+00
8.6e-01
cases:30.71%
controls:22.17%
cases:12.20%
controls:5.75%
—
—
cases:8.27%
controls:0.00%
cases:3.98%
controls:0.75%
cases:19.01%
controls:4.77%
cases:36.54%
controls:19.64%
78
563
176
1977
31
146
223
2394
—
21
0
233
2540
10
19
241
2516
46
117
196
2335
76
412
132
1686
Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay
3255-7 [3016407]
—
—
—
—
—
2.3e+00
2.6e+00
—
—
—
—
—
—
—
—
—
—
cases:2.07%
controls:0.20%
cases:4.81%
controls:0.38%
—
—
—
—
—
5
5
237
2447
10
8
198
2090
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
7.6e-01
1.6e+00
—
—
—
2.0e+00
1.3e+00
cases:7.87%
controls:3.86%
cases:5.12%
controls:1.06%
—
—
—
—
—
—
cases:6.61%
controls:0.98%
cases:12.98%
controls:4.05%
20
98
234
2442
13
27
241
2513
—
—
—
16
24
226
2428
27
85
181
2013
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
7.0e-01
1.5e+00
—
—
1.8e+00
1.3e+00
1.2e+00
cases:12.60%
controls:6.69%
cases:11.81%
controls:2.91%
—
—
—
—
cases:2.39%
controls:0.39%
cases:10.33%
controls:2.94%
cases:21.63%
controls:7.53%
32
170
222
2370
30
74
224
2466
—
—
6
10
245
2525
25
72
217
2380
45
158
163
1940
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
1.5e-01
8.0e-01
2.2e+00
—
—
1.3e+00
1.2e+00
cases:10.24%
controls:8.94%
cases:7.09%
controls:3.31%
cases:3.15%
controls:0.35%
—
—
—
—
cases:10.74%
controls:3.22%
cases:20.67%
controls:7.29%
26
227
228
2313
18
84
236
2456
8
9
246
2531
—
—
26
79
216
2373
43
153
165
1945
Other and unspecified abdominal pain
R10.4 [45568113]
5.7e-01
1.8e+00
—
1.0e+50
—
1.7e+00
1.1e+00
cases:9.06%
controls:5.35%
cases:10.24%
controls:1.81%
—
—
cases:3.15%
controls:0.00%
—
—
cases:9.09%
controls:1.75%
cases:15.87%
controls:5.96%
23
136
231
2404
26
46
228
2494
—
8
0
246
2540
—
22
43
220
2409
33
125
175
1973
Bacteria [Presence] in Urine
87829-8 [36304419]
7.5e-01
1.8e+00
—
—
—
1.5e+00
1.3e+00
cases:9.84%
controls:4.88%
cases:11.02%
controls:2.05%
—
—
—
—
—
—
cases:8.26%
controls:2.00%
cases:16.35%
controls:5.15%
25
124
229
2416
28
52
226
2488
—
—
—
20
49
222
2403
34
108
174
1990
Inpatient Hospital
21 [8717]
3.8e-01
7.3e-01
1.6e+00
1.0e+50
1.7e+00
1.3e+00
7.9e-01
cases:36.22%
controls:27.87%
cases:16.14%
controls:8.46%
cases:3.15%
controls:0.67%
cases:16.14%
controls:0.00%
cases:5.98%
controls:1.18%
cases:21.90%
controls:7.14%
cases:39.90%
controls:23.12%
92
708
162
1832
41
215
213
2325
8
17
246
2523
41
0
213
2540
15
30
236
2505
53
175
189
2277
83
485
125
1613
Emergency Room Visit
ER [9203]
3.1e-01
1.1e+00
1.7e+00
—
1.2e+00
9.4e-01
6.7e-01
cases:36.61%
controls:29.84%
cases:22.83%
controls:8.62%
cases:5.91%
controls:1.10%
—
—
cases:3.19%
controls:0.99%
cases:22.31%
controls:10.07%
cases:43.27%
controls:28.03%
93
758
161
1782
58
219
196
2321
15
28
239
2512
—
8
25
243
2510
54
247
188
2205
90
588
118
1510
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
1.8e+00
—
—
—
—
—
2.7e+00
cases:3.15%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
cases:6.73%
controls:0.48%
8
14
246
2526
—
—
—
—
—
14
10
194
2088
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
4.6e-01
1.0e+00
1.7e+00
—
1.4e+00
8.8e-01
8.2e-01
cases:20.47%
controls:13.98%
cases:14.96%
controls:6.06%
cases:3.94%
controls:0.75%
—
—
cases:3.59%
controls:0.95%
cases:13.22%
controls:5.95%
cases:29.81%
controls:15.73%
52
355
202
2185
38
154
216
2386
10
19
244
2521
—
9
24
242
2511
32
146
210
2306
62
330
146
1768
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
6.3e-01
1.5e+00
—
1.0e+50
—
1.5e+00
1.3e+00
cases:9.45%
controls:5.28%
cases:9.06%
controls:2.09%
—
—
cases:3.54%
controls:0.00%
—
—
cases:9.50%
controls:2.32%
cases:21.15%
controls:6.82%
24
134
230
2406
23
53
231
2487
—
9
0
245
2540
—
23
57
219
2395
44
143
164
1955
Supplier / Service Provider
OMOP5117446 [33004]
-9.7e-01
-6.8e-01
—
—
—
2.3e+00
3.0e+00
cases:12.99%
controls:28.27%
cases:3.54%
controls:6.73%
—
—
—
—
—
—
cases:5.37%
controls:0.57%
cases:18.27%
controls:1.14%
33
718
221
1822
9
171
245
2369
—
—
—
13
14
229
2438
38
24
170
2074
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
9.7e-01
1.5e+00
1.0e+50
—
—
2.3e+00
1.9e+00
cases:3.94%
controls:1.54%
cases:3.15%
controls:0.71%
cases:3.15%
controls:0.00%
—
—
—
—
cases:4.55%
controls:0.49%
cases:10.10%
controls:1.67%
10
39
244
2501
8
18
246
2522
8
0
246
2540
—
—
11
12
231
2440
21
35
187
2063
Extensive abdominal CT
JN3BD [2001305556]
1.5e+00
—
—
—
—
—
2.6e+00
cases:3.94%
controls:0.87%
—
—
—
—
—
—
—
—
—
—
cases:7.21%
controls:0.57%
10
22
244
2518
—
—
—
—
—
15
12
193
2086
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
6.5e-01
1.6e+00
—
—
1.9e+00
1.3e+00
1.2e+00
cases:7.48%
controls:4.06%
cases:6.30%
controls:1.30%
—
—
—
—
cases:1.99%
controls:0.32%
cases:5.79%
controls:1.59%
cases:10.10%
controls:3.34%
19
103
235
2437
16
33
238
2507
—
—
5
8
246
2527
14
39
228
2413
21
70
187
2028
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
3.6e-01
—
—
—
—
2.3e+00
1.8e+00
cases:1.97%
controls:1.38%
—
—
—
—
—
—
—
—
cases:2.89%
controls:0.29%
cases:6.73%
controls:1.19%
5
35
249
2505
—
—
—
—
7
7
235
2445
14
25
194
2073
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
1.4e-01
6.7e-01
1.8e+00
—
1.1e+00
5.7e-01
4.2e-01
cases:32.28%
controls:29.37%
cases:35.83%
controls:22.28%
cases:20.47%
controls:4.13%
—
—
cases:10.76%
controls:3.87%
cases:33.88%
controls:22.39%
cases:48.56%
controls:38.23%
82
746
172
1794
91
566
163
1974
52
105
202
2435
—
27
98
224
2437
82
549
160
1903
101
802
107
1296
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
1.3e-01
6.4e-01
1.8e+00
—
1.1e+00
5.7e-01
4.3e-01
cases:32.28%
controls:29.61%
cases:35.83%
controls:22.72%
cases:20.87%
controls:4.17%
—
—
cases:10.76%
controls:3.87%
cases:33.88%
controls:22.51%
cases:49.04%
controls:38.61%
82
752
172
1788
91
577
163
1963
53
106
201
2434
—
27
98
224
2437
82
552
160
1900
102
810
106
1288
One hour or less
ZXE00 [2001311394]
4.3e-01
1.4e+00
—
—
—
1.7e+00
1.1e+00
cases:8.66%
controls:5.83%
cases:4.33%
controls:1.14%
—
—
—
—
—
—
cases:5.37%
controls:1.06%
cases:12.98%
controls:4.96%
22
148
232
2392
11
29
243
2511
—
—
—
13
26
229
2426
27
104
181
1994
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
6.8e-01
1.4e+00
—
—
—
1.4e+00
1.3e+00
cases:9.06%
controls:4.80%
cases:7.09%
controls:1.89%
—
—
—
—
—
—
cases:7.44%
controls:1.92%
cases:16.35%
controls:5.20%
23
122
231
2418
18
48
236
2492
—
—
—
18
47
224
2405
34
109
174
1989
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
6.8e-01
1.6e+00
—
—
1.9e+00
1.4e+00
1.1e+00
cases:10.63%
controls:5.67%
cases:11.81%
controls:2.64%
—
—
—
—
cases:2.39%
controls:0.36%
cases:9.50%
controls:2.57%
cases:17.31%
controls:6.72%
27
144
227
2396
30
67
224
2473
—
—
6
9
245
2526
23
63
219
2389
36
141
172
1957
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
3.2e-01
1.1e+00
—
—
—
1.5e+00
1.3e+00
cases:7.48%
controls:5.55%
cases:6.30%
controls:2.28%
—
—
—
—
—
—
cases:8.68%
controls:2.00%
cases:15.87%
controls:4.91%
19
141
235
2399
16
58
238
2482
—
—
—
21
49
221
2403
33
103
175
1995
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
1.2e-01
5.0e-01
1.7e+00
—
1.0e+00
6.0e-01
3.1e-01
cases:25.59%
controls:23.31%
cases:27.56%
controls:18.74%
cases:18.90%
controls:3.94%
—
—
cases:8.76%
controls:3.39%
cases:29.75%
controls:18.84%
cases:37.02%
controls:30.03%
65
592
189
1948
70
476
184
2064
48
100
206
2440
—
22
86
229
2449
72
462
170
1990
77
630
131
1468
Laboratory Visit
OMOP4822461 [32036]
4.8e-02
3.5e-01
1.4e+00
2.4e+00
5.9e-01
2.4e-01
1.9e-01
cases:38.58%
controls:37.44%
cases:43.31%
controls:34.96%
cases:32.28%
controls:10.59%
cases:8.27%
controls:0.79%
cases:17.53%
controls:10.57%
cases:41.74%
controls:35.97%
cases:53.37%
controls:48.57%
98
951
156
1589
110
888
144
1652
82
269
172
2271
21
20
233
2520
44
268
207
2267
101
882
141
1570
111
1019
97
1079
pH of Arterial blood
2744-1 [3019977]
4.9e-01
1.8e+00
—
—
—
2.0e+00
1.2e+00
cases:1.97%
controls:1.22%
cases:2.76%
controls:0.47%
—
—
—
—
—
—
cases:3.31%
controls:0.45%
cases:5.77%
controls:1.81%
5
31
249
2509
7
12
247
2528
—
—
—
8
11
234
2441
12
38
196
2060
Physiotherapist
Z3226 [2001311560]
1.1e+00
2.2e+00
—
—
—
1.6e+00
9.0e-01
cases:4.33%
controls:1.54%
cases:3.94%
controls:0.47%
—
—
—
—
—
—
cases:3.31%
controls:0.65%
cases:2.88%
controls:1.19%
11
39
243
2501
10
12
244
2528
—
—
—
8
16
234
2436
6
25
202
2073
Leukocytes [#/volume] in Urine
30405-5 [3018095]
5.9e-01
1.6e+00
—
—
1.6e+00
1.2e+00
9.1e-01
cases:11.02%
controls:6.42%
cases:14.17%
controls:3.19%
—
—
—
—
cases:2.39%
controls:0.51%
cases:10.74%
controls:3.38%
cases:18.27%
controls:8.25%
28
163
226
2377
36
81
218
2459
—
—
6
13
245
2522
26
83
216
2369
38
173
170
1925
Pain localized to upper abdomen
R10.1 [45568111]
7.8e-01
2.7e+00
—
—
—
1.5e+00
1.1e+00
cases:3.54%
controls:1.65%
cases:7.87%
controls:0.59%
—
—
—
—
—
—
cases:2.48%
controls:0.57%
cases:7.69%
controls:2.72%
9
42
245
2498
20
15
234
2525
—
—
—
6
14
236
2438
16
57
192
2041
General anesthesia, balanced
WX408 [2001310808]
6.6e-01
1.3e+00
—
—
—
2.2e+00
1.5e+00
cases:5.12%
controls:2.72%
cases:2.36%
controls:0.63%
—
—
—
—
—
—
cases:3.31%
controls:0.37%
cases:9.13%
controls:2.19%
13
69
241
2471
6
16
248
2524
—
—
—
8
9
234
2443
19
46
189
2052
Case Management Agency
251B00000X [38004193]
9.9e-02
1.8e-01
4.0e-01
3.7e+00
2.2e-01
2.5e-01
1.1e-01
cases:59.45%
controls:57.05%
cases:54.33%
controls:49.96%
cases:27.95%
controls:20.71%
cases:31.89%
controls:1.14%
cases:25.50%
controls:21.54%
cases:57.44%
controls:51.35%
cases:70.67%
controls:68.30%
151
1449
103
1091
138
1269
116
1271
71
526
183
2014
81
29
173
2511
64
546
187
1989
139
1259
103
1193
147
1433
61
665
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
7.3e-01
1.5e+00
—
—
—
1.8e+00
1.9e+00
cases:3.94%
controls:1.93%
cases:2.36%
controls:0.55%
—
—
—
—
—
—
cases:4.13%
controls:0.69%
cases:11.06%
controls:1.86%
10
49
244
2491
6
14
248
2526
—
—
—
10
17
232
2435
23
39
185
2059
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
4.6e-01
1.6e+00
—
—
—
1.9e+00
1.8e+00
cases:4.72%
controls:3.03%
cases:3.15%
controls:0.67%
—
—
—
—
—
—
cases:4.13%
controls:0.65%
cases:11.06%
controls:2.05%
12
77
242
2463
8
17
246
2523
—
—
—
10
16
232
2436
23
43
185
2055
Kidney transplant status
Z94.0 [45566477]
—
—
—
1.0e+50
—
—
3.6e+00
—
—
—
—
—
—
cases:2.36%
controls:0.00%
—
—
—
—
cases:8.17%
controls:0.24%
—
—
—
6
0
248
2540
—
—
17
5
191
2093
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
—
—
—
—
—
2.0e+00
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:2.48%
controls:0.33%
cases:4.81%
controls:1.05%
—
—
—
—
—
6
8
236
2444
10
22
198
2076
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
9.7e-01
1.7e+00
—
—
—
2.0e+00
1.5e+00
cases:2.36%
controls:0.91%
cases:2.76%
controls:0.51%
—
—
—
—
—
—
cases:3.31%
controls:0.45%
cases:6.25%
controls:1.48%
6
23
248
2517
7
13
247
2527
—
—
—
8
11
234
2441
13
31
195
2067
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
2.2e-01
1.1e+00
1.7e+00
—
1.1e+00
7.0e-01
6.7e-01
cases:11.81%
controls:9.69%
cases:14.57%
controls:5.39%
cases:3.15%
controls:0.59%
—
—
cases:2.39%
controls:0.83%
cases:9.92%
controls:5.18%
cases:24.52%
controls:14.30%
30
246
224
2294
37
137
217
2403
8
15
246
2525
—
6
21
245
2514
24
127
218
2325
51
300
157
1798
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
2.6e-01
1.1e+00
1.7e+00
—
1.1e+00
6.8e-01
6.6e-01
cases:11.81%
controls:9.33%
cases:14.17%
controls:5.39%
cases:3.15%
controls:0.59%
—
—
cases:2.39%
controls:0.83%
cases:9.92%
controls:5.26%
cases:23.56%
controls:13.78%
30
237
224
2303
36
137
218
2403
8
15
246
2525
—
6
21
245
2514
24
129
218
2323
49
289
159
1809
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
8.3e-01
1.4e+00
—
—
—
1.9e+00
1.5e+00
cases:5.51%
controls:2.48%
cases:3.15%
controls:0.79%
—
—
—
—
—
—
cases:4.13%
controls:0.65%
cases:11.06%
controls:2.62%
14
63
240
2477
8
20
246
2520
—
—
—
10
16
232
2436
23
55
185
2043
Pathology report gross observation
24419-4 [3002256]
4.4e-01
—
—
—
—
2.0e+00
1.4e+00
cases:3.15%
controls:2.05%
—
—
—
—
—
—
—
—
cases:4.55%
controls:0.61%
cases:6.73%
controls:1.81%
8
52
246
2488
—
—
—
—
11
15
231
2437
14
38
194
2060
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)/1.73 sq M
77147-7 [46236952]
7.3e-01
1.2e+00
—
—
—
2.1e+00
1.3e+00
cases:3.15%
controls:1.54%
cases:1.97%
controls:0.59%
—
—
—
—
—
—
cases:2.89%
controls:0.37%
cases:5.29%
controls:1.48%
8
39
246
2501
5
15
249
2525
—
—
—
7
9
235
2443
11
31
197
2067
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2.1e-01
1.0e+00
1.7e+00
—
1.1e+00
6.7e-01
6.4e-01
cases:11.42%
controls:9.45%
cases:14.17%
controls:5.47%
cases:3.15%
controls:0.59%
—
—
cases:2.39%
controls:0.83%
cases:9.92%
controls:5.34%
cases:24.04%
controls:14.30%
29
240
225
2300
36
139
218
2401
8
15
246
2525
—
6
21
245
2514
24
131
218
2321
50
300
158
1798
ANTIHYPERTENSIVE_DRUG - yes
ANTIHYPERTENSIVE_DRUG-1 [2002330215]
3.4e+00
—
—
—
—
—
—
cases:5.51%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
14
5
240
2535
—
—
—
—
—
—
furosemide; oral, parenteral
C03CA01 [21601518]
1.0e+00
7.8e-01
1.4e+00
—
—
6.0e-01
9.3e-01
cases:11.42%
controls:4.53%
cases:8.27%
controls:3.98%
cases:3.94%
controls:0.98%
—
—
—
—
cases:7.44%
controls:4.24%
cases:12.50%
controls:5.34%
29
115
225
2425
21
101
233
2439
10
25
244
2515
—
—
18
104
224
2348
26
112
182
1986
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
5.0e-01
1.3e+00
—
—
—
2.0e+00
1.3e+00
cases:2.76%
controls:1.69%
cases:3.15%
controls:0.91%
—
—
—
—
—
—
cases:5.79%
controls:0.82%
cases:9.62%
controls:2.81%
7
43
247
2497
8
23
246
2517
—
—
—
14
20
228
2432
20
59
188
2039
Urology
34 [38004474]
6.5e-01
1.3e+00
—
—
1.7e+00
1.0e+00
1.0e+00
cases:9.06%
controls:4.92%
cases:7.09%
controls:2.13%
—
—
—
—
cases:1.99%
controls:0.36%
cases:6.61%
controls:2.53%
cases:12.98%
controls:5.20%
23
125
231
2415
18
54
236
2486
—
—
5
9
246
2526
16
62
226
2390
27
109
181
1989
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
9.7e-02
5.9e-01
1.8e+00
—
8.3e-01
4.0e-01
4.0e-01
cases:32.68%
controls:30.59%
cases:35.83%
controls:23.70%
cases:21.26%
controls:4.17%
—
—
cases:9.16%
controls:4.22%
cases:31.82%
controls:23.86%
cases:50.00%
controls:40.18%
83
777
171
1763
91
602
163
1938
54
106
200
2434
—
23
107
228
2428
77
585
165
1867
104
843
104
1255
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
6.5e-01
1.2e+00
—
—
—
1.0e+00
9.5e-01
cases:7.09%
controls:3.82%
cases:7.87%
controls:2.40%
—
—
—
—
—
—
cases:6.61%
controls:2.45%
cases:15.38%
controls:6.58%
18
97
236
2443
20
61
234
2479
—
—
—
16
60
226
2392
32
138
176
1960
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
3.5e-01
8.0e-01
1.7e+00
—
1.6e+00
6.6e-01
7.3e-01
cases:11.81%
controls:8.62%
cases:11.02%
controls:5.28%
cases:3.94%
controls:0.75%
—
—
cases:2.79%
controls:0.55%
cases:9.50%
controls:5.14%
cases:22.60%
controls:12.35%
30
219
224
2321
28
134
226
2406
10
19
244
2521
—
7
14
244
2521
23
126
219
2326
47
259
161
1839
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
5.8e-01
1.0e+00
—
—
2.0e+00
1.2e+00
8.4e-01
cases:9.45%
controls:5.51%
cases:5.91%
controls:2.20%
—
—
—
—
cases:1.99%
controls:0.28%
cases:8.26%
controls:2.53%
cases:13.46%
controls:6.29%
24
140
230
2400
15
56
239
2484
—
—
5
7
246
2528
20
62
222
2390
28
132
180
1966
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
9.4e-02
7.6e-01
1.7e+00
—
—
4.5e-01
6.3e-01
cases:17.32%
controls:16.02%
cases:15.35%
controls:7.80%
cases:3.94%
controls:0.75%
—
—
—
—
cases:11.16%
controls:7.42%
cases:27.88%
controls:17.11%
44
407
210
2133
39
198
215
2342
10
19
244
2521
—
—
27
182
215
2270
58
359
150
1739
Epstein Barr virus nuclear IgG Ab [Units/volume] in Serum
31374-2 [3007080]
—
—
—
—
—
—
3.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:0.24%
—
—
—
—
—
—
10
5
198
2093
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
4.9e-01
1.6e+00
—
—
—
1.7e+00
1.3e+00
cases:1.97%
controls:1.22%
cases:2.76%
controls:0.59%
—
—
—
—
—
—
cases:3.72%
controls:0.69%
cases:8.65%
controls:2.48%
5
31
249
2509
7
15
247
2525
—
—
—
9
17
233
2435
18
52
190
2046
Infectious Disease
44 [38004484]
1.3e+00
1.7e+00
—
—
—
1.6e+00
1.1e+00
cases:4.33%
controls:1.22%
cases:3.15%
controls:0.59%
—
—
—
—
—
—
cases:2.48%
controls:0.49%
cases:3.85%
controls:1.33%
11
31
243
2509
8
15
246
2525
—
—
—
6
12
236
2440
8
28
200
2070
darbepoetin alfa; parenteral
B03XA02 [21601134]
—
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.33%
controls:0.24%
—
—
—
—
—
—
9
5
199
2093
Cytomegalovirus IgG Ab [Titer] in Serum or Plasma
22246-3 [3017918]
—
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.33%
controls:0.24%
—
—
—
—
—
—
9
5
199
2093
Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma
7853-5 [3015635]
2.0e+00
—
—
—
—
—
2.9e+00
cases:1.97%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:4.33%
controls:0.24%
5
7
249
2533
—
—
—
—
—
9
5
199
2093
More than one and less than three hours
ZXE10 [2001311401]
5.1e-01
9.4e-01
—
—
—
1.8e+00
1.1e+00
cases:8.27%
controls:5.12%
cases:3.15%
controls:1.26%
—
—
—
—
—
—
cases:3.31%
controls:0.57%
cases:11.06%
controls:4.00%
21
130
233
2410
8
32
246
2508
—
—
—
8
14
234
2438
23
84
185
2014
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
1.5e-01
4.6e-01
1.7e+00
—
1.1e+00
4.7e-01
3.9e-01
cases:29.53%
controls:26.42%
cases:27.56%
controls:19.29%
cases:16.93%
controls:3.43%
—
—
cases:9.96%
controls:3.47%
cases:27.69%
controls:19.33%
cases:42.31%
controls:33.17%
75
671
179
1869
70
490
184
2050
43
87
211
2453
—
25
88
226
2447
67
474
175
1978
88
696
120
1402
Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay
5159-9 [3007844]
—
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:0.29%
—
—
—
—
—
—
10
6
198
2092
Ammonium ion [Moles/volume] in Plasma
1845-7 [3023183]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.29%
controls:0.33%
—
—
—
—
—
—
11
7
197
2091
Other chronic renal failure
N18.8 [45534123]
2.8e+00
—
—
—
—
—
—
cases:3.15%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
8
5
246
2535
—
—
—
—
—
—
Osmolality of Urine
2695-5 [3026782]
5.0e-01
1.5e+00
—
—
—
1.2e+00
1.2e+00
cases:6.69%
controls:4.17%
cases:5.51%
controls:1.26%
—
—
—
—
—
—
cases:4.55%
controls:1.47%
cases:9.13%
controls:2.81%
17
106
237
2434
14
32
240
2508
—
—
—
11
36
231
2416
19
59
189
2039
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
4.7e-01
9.9e-01
—
—
—
1.7e+00
1.0e+00
cases:8.66%
controls:5.59%
cases:4.33%
controls:1.65%
—
—
—
—
—
—
cases:7.02%
controls:1.43%
cases:13.94%
controls:5.43%
22
142
232
2398
11
42
243
2498
—
—
—
17
35
225
2417
29
114
179
1984
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
7.2e-01
9.4e-01
—
—
—
1.4e+00
1.3e+00
cases:7.48%
controls:3.78%
cases:4.33%
controls:1.73%
—
—
—
—
—
—
cases:6.61%
controls:1.75%
cases:12.02%
controls:3.57%
19
96
235
2444
11
44
243
2496
—
—
—
16
43
226
2409
25
75
183
2023
Gastro-oesophageal reflux disease with oesophagitis
K21.0 [45543296]
—
—
—
—
—
2.7e+00
7.1e-01
—
—
—
—
—
—
—
—
—
—
cases:2.89%
controls:0.20%
cases:2.40%
controls:1.19%
—
—
—
—
—
7
5
235
2447
5
25
203
2073
Chronic hypertension
205 [2001600203]
3.1e-01
-1.0e+50
—
—
—
2.7e+00
7.1e-01
cases:1.97%
controls:1.46%
cases:0.00%
controls:0.20%
—
—
—
—
—
—
cases:2.89%
controls:0.20%
cases:2.40%
controls:1.19%
5
37
249
2503
0
5
254
2535
—
—
—
7
5
235
2447
5
25
203
2073
Procedure duration 10 to 19 minutes
ZXE02 [2001311396]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.37%
controls:0.24%
—
—
—
—
—
—
7
5
201
2093
Epstein Barr virus Ab [Presence] in Serum
49178-7 [3048929]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.77%
controls:0.43%
—
—
—
—
—
—
12
9
196
2089
ABO and Rh group [Type] in Blood
882-1 [3003694]
-2.0e-01
1.5e+00
—
—
-1.0e+50
1.2e+00
1.2e+00
cases:3.94%
controls:4.76%
cases:4.72%
controls:1.14%
—
—
—
—
cases:0.00%
controls:0.20%
cases:4.13%
controls:1.22%
cases:9.62%
controls:3.24%
10
121
244
2419
12
29
242
2511
—
—
0
5
251
2530
10
30
232
2422
20
68
188
2030
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
-2.9e-02
6.4e-01
1.4e+00
—
9.1e-01
4.2e-01
5.6e-01
cases:18.11%
controls:18.54%
cases:15.35%
controls:8.70%
cases:4.33%
controls:1.10%
—
—
cases:3.19%
controls:1.30%
cases:12.81%
controls:8.77%
cases:30.77%
controls:20.21%
46
471
208
2069
39
221
215
2319
11
28
243
2512
—
8
33
243
2502
31
215
211
2237
64
424
144
1674
Extracorporeal dialysis
Z49.1 [45537649]
—
2.6e+00
—
—
—
—
—
—
—
cases:3.54%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
9
7
245
2533
—
—
—
—
—
Reagin Ab [Titer] in Serum by VDRL
50690-7 [3029634]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.88%
controls:0.24%
—
—
—
—
—
—
6
5
202
2093
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]
—
—
—
—
—
2.5e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:2.89%
controls:0.24%
cases:3.37%
controls:1.05%
—
—
—
—
—
7
6
235
2446
7
22
201
2076
Antithrombin actual/normal in Platelet poor plasma by Chromogenic method
27811-9 [3000515]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.33%
controls:0.38%
—
—
—
—
—
—
9
8
199
2090
Emergency Medicine
93 [38004510]
3.8e-01
9.8e-01
1.3e+00
1.0e+50
1.2e+00
8.5e-01
6.3e-01
cases:16.54%
controls:11.93%
cases:14.96%
controls:6.18%
cases:3.54%
controls:0.98%
cases:3.54%
controls:0.00%
cases:2.39%
controls:0.71%
cases:14.05%
controls:6.53%
cases:26.92%
controls:16.40%
42
303
212
2237
38
157
216
2383
9
25
245
2515
9
0
245
2540
6
18
245
2517
34
160
208
2292
56
344
152
1754
Hepatitis B virus core and surface Ab and surface Ag panel - Serum
77190-7 [46237023]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:0.43%
—
—
—
—
—
—
10
9
198
2089
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]
—
—
—
—
—
2.3e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:2.89%
controls:0.29%
cases:3.37%
controls:1.19%
—
—
—
—
—
7
7
235
2445
7
25
201
2073
Hepatitis B virus core IgM Ab [Presence] in Serum
31204-1 [3013527]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.37%
controls:0.33%
—
—
—
—
—
—
7
7
201
2091
Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis
50796-2 [3029338]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.88%
controls:0.29%
—
—
—
—
—
—
6
6
202
2092
Other spondylosis with radiculopathy
M47.2 [45591850]
—
—
—
—
—
2.3e+00
1.3e+00
—
—
—
—
—
—
—
—
—
—
cases:2.07%
controls:0.20%
cases:2.40%
controls:0.67%
—
—
—
—
—
5
5
237
2447
5
14
203
2084
Protein.monoclonal band 4 [Mass/volume] in Serum or Plasma by Electrophoresis
50797-0 [3029379]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.40%
controls:0.24%
—
—
—
—
—
—
5
5
203
2093
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
—
2.3e+00
—
—
—
1.9e+00
1.2e+00
—
—
cases:2.36%
controls:0.24%
—
—
—
—
—
—
cases:2.48%
controls:0.37%
cases:2.88%
controls:0.86%
—
6
6
248
2534
—
—
—
6
9
236
2443
6
18
202
2080
Emergency Room and Inpatient Visit
ERIP [262]
2.9e-01
1.3e+00
—
1.0e+50
2.0e+00
6.1e-01
9.5e-01
cases:6.69%
controls:5.12%
cases:7.48%
controls:2.09%
—
—
cases:2.76%
controls:0.00%
cases:1.99%
controls:0.28%
cases:4.55%
controls:2.53%
cases:14.42%
controls:6.10%
17
130
237
2410
19
53
235
2487
—
7
0
247
2540
5
7
246
2528
11
62
231
2390
30
128
178
1970
Haptoglobin [Mass/volume] in Serum or Plasma
4542-7 [3012336]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.77%
controls:0.62%
—
—
—
—
—
—
12
13
196
2085
pantoprazole; oral, parenteral
A02BC02 [21600097]
4.7e-01
7.2e-01
5.0e-01
—
1.2e-01
9.1e-01
6.2e-01
cases:23.23%
controls:15.87%
cases:18.11%
controls:9.72%
cases:3.15%
controls:1.93%
—
—
cases:2.39%
controls:2.13%
cases:20.25%
controls:9.30%
cases:30.29%
controls:18.97%
59
403
195
2137
46
247
208
2293
8
49
246
2491
—
6
54
245
2481
49
228
193
2224
63
398
145
1700
Apolipoprotein B [Mass/volume] in Serum or Plasma
1884-6 [3014791]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.85%
controls:0.43%
—
—
—
—
—
—
8
9
200
2089
Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Electrophoresis
51435-6 [3029713]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.85%
controls:0.43%
—
—
—
—
—
—
8
9
200
2089
Microscopic observation [Identifier] in Isolate by Gram stain
87975-9 [36305247]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.85%
controls:0.43%
—
—
—
—
—
—
8
9
200
2089
Fractional oxyhemoglobin in Arterial blood
2714-4 [3014007]
—
—
—
—
—
2.2e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:2.89%
controls:0.33%
cases:3.37%
controls:1.14%
—
—
—
—
—
7
8
235
2444
7
24
201
2074
Other extensive ultrasound examination of artery
PG1DE [2001309713]
—
—
—
—
—
-1.0e+50
2.2e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:2.88%
controls:0.33%
—
—
—
—
—
0
6
242
2446
6
7
202
2091
Paranasal sinuses X-ray examination in one projection
DM1QA [2001301761]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.88%
controls:0.33%
—
—
—
—
—
—
6
7
202
2091
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
-1.7e-01
7.8e-01
2.2e+00
—
—
8.4e-02
6.1e-01
cases:4.72%
controls:5.55%
cases:5.51%
controls:2.60%
cases:2.36%
controls:0.28%
—
—
—
—
cases:2.48%
controls:2.28%
cases:11.06%
controls:6.34%
12
141
242
2399
14
66
240
2474
6
7
248
2533
—
—
6
56
236
2396
23
133
185
1965
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
—
2.2e+00
—
—
—
—
1.1e+00
—
—
cases:2.36%
controls:0.28%
—
—
—
—
—
—
—
—
cases:5.29%
controls:1.81%
—
6
7
248
2533
—
—
—
—
11
38
197
2060
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
—
2.2e+00
—
—
—
—
9.8e-01
—
—
cases:2.36%
controls:0.28%
—
—
—
—
—
—
—
—
cases:5.29%
controls:2.05%
—
6
7
248
2533
—
—
—
—
11
43
197
2055
Acute tubulo-interstitial nephritis
N10 [45543856]
1.2e+00
—
—
—
—
—
2.1e+00
cases:2.36%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:9.13%
controls:1.24%
6
18
248
2522
—
—
—
—
—
19
26
189
2072
cefalexin; oral
J01DB01 [21602870]
4.8e-01
4.5e-01
1.1e+00
—
1.6e+00
3.9e-01
4.2e-01
cases:38.19%
controls:27.56%
cases:14.17%
controls:9.49%
cases:3.54%
controls:1.22%
—
—
cases:3.59%
controls:0.75%
cases:11.57%
controls:8.16%
cases:35.58%
controls:26.55%
97
700
157
1840
36
241
218
2299
9
31
245
2509
—
9
19
242
2516
28
200
214
2252
74
557
134
1541
Lactate [Moles/volume] in Blood
32693-4 [3047181]
-1.0e+50
—
—
—
—
—
2.0e+00
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
cases:2.88%
controls:0.38%
0
6
254
2534
—
—
—
—
—
6
8
202
2090
Examination and observation for other specified reasons
Z04.8 [45552063]
8.7e-01
1.8e+00
—
—
—
2.0e+00
7.2e-01
cases:3.15%
controls:1.34%
cases:2.36%
controls:0.39%
—
—
—
—
—
—
cases:2.89%
controls:0.41%
cases:3.37%
controls:1.67%
8
34
246
2506
6
10
248
2530
—
—
—
7
10
235
2442
7
35
201
2063
Urinary tract ultrasound examination
KH1AE [2001306329]
—
-1.0e+50
—
—
—
—
2.0e+00
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
cases:3.37%
controls:0.48%
—
0
5
254
2535
—
—
—
—
7
10
201
2088
Mitochondria Ab [Titer] in Serum
20483-4 [3034770]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.37%
controls:0.48%
—
—
—
—
—
—
7
10
201
2088
Differential panel, method unspecified - Blood
69738-3 [42870588]
3.7e-01
1.0e+00
9.3e-01
—
1.7e+00
9.6e-01
7.1e-01
cases:9.84%
controls:7.01%
cases:8.66%
controls:3.35%
cases:1.97%
controls:0.79%
—
—
cases:2.79%
controls:0.51%
cases:8.68%
controls:3.51%
cases:14.42%
controls:7.67%
25
178
229
2362
22
85
232
2455
5
20
249
2520
—
7
13
244
2522
21
86
221
2366
30
161
178
1937
pH of Urine
2756-5 [3015736]
3.0e-01
1.2e+00
1.7e+00
—
1.2e+00
7.6e-01
7.2e-01
cases:9.45%
controls:7.20%
cases:12.20%
controls:3.94%
cases:2.36%
controls:0.43%
—
—
cases:1.99%
controls:0.59%
cases:7.85%
controls:3.83%
cases:19.71%
controls:10.68%
24
183
230
2357
31
100
223
2440
6
11
248
2529
—
5
15
246
2520
19
94
223
2358
41
224
167
1874
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
4.5e-01
1.7e+00
—
—
—
1.9e+00
1.2e+00
cases:1.97%
controls:1.26%
cases:2.36%
controls:0.43%
—
—
—
—
—
—
cases:3.31%
controls:0.49%
cases:5.77%
controls:1.81%
5
32
249
2508
6
11
248
2529
—
—
—
8
12
234
2440
12
38
196
2060
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
4.5e-01
1.7e+00
—
—
—
1.9e+00
1.2e+00
cases:1.97%
controls:1.26%
cases:2.36%
controls:0.43%
—
—
—
—
—
—
cases:3.31%
controls:0.49%
cases:5.77%
controls:1.81%
5
32
249
2508
6
11
248
2529
—
—
—
8
12
234
2440
12
38
196
2060
Cathetrisation of artery
TPH07 [2001309747]
1.3e+00
—
—
—
—
1.9e+00
1.1e+00
cases:3.15%
controls:0.91%
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.49%
cases:2.40%
controls:0.81%
8
23
246
2517
—
—
—
—
8
12
234
2440
5
17
203
2081
More than three and less than five hours
ZXE20 [2001311408]
5.5e-01
—
—
—
—
—
1.9e+00
cases:2.36%
controls:1.38%
—
—
—
—
—
—
—
—
—
—
cases:4.33%
controls:0.67%
6
35
248
2505
—
—
—
—
—
9
14
199
2084
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
8.7e-01
—
—
—
—
1.2e+00
1.9e+00
cases:3.94%
controls:1.69%
—
—
—
—
—
—
—
—
cases:2.48%
controls:0.77%
cases:7.69%
controls:1.29%
10
43
244
2497
—
—
—
—
6
19
236
2433
16
27
192
2071
Bacteria identified in Isolate by Culture
43409-2 [3042936]
7.3e-01
9.3e-01
—
—
—
1.3e+00
1.8e+00
cases:4.72%
controls:2.32%
cases:1.97%
controls:0.79%
—
—
—
—
—
—
cases:3.31%
controls:0.90%
cases:11.54%
controls:2.05%
12
59
242
2481
5
20
249
2520
—
—
—
8
22
234
2430
24
43
184
2055
General Practice Dentistry
1223G0001X [38003675]
1.8e+00
—
—
—
—
—
1.6e+00
cases:3.54%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
cases:2.88%
controls:0.57%
9
15
245
2525
—
—
—
—
—
6
12
202
2086
Immunohistochemistry procedure
117617002 [4035726]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.29%
controls:0.91%
—
—
—
—
—
—
11
19
197
2079
Fractional oxyhemoglobin in Venous blood
2716-9 [3019230]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.37%
controls:0.57%
—
—
—
—
—
—
7
12
201
2086
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
1.1e+00
—
—
—
—
—
1.8e+00
cases:2.76%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
cases:3.37%
controls:0.57%
7
24
247
2516
—
—
—
—
—
7
12
201
2086
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
—
1.8e+00
—
—
—
8.0e-01
1.0e+00
—
—
cases:2.76%
controls:0.47%
—
—
—
—
—
—
cases:2.07%
controls:0.94%
cases:6.73%
controls:2.57%
—
7
12
247
2528
—
—
—
5
23
237
2429
14
54
194
2044
Microorganisms panel - Urine sediment
58435-9 [40761536]
3.4e-01
1.8e+00
—
—
—
—
1.4e+00
cases:2.36%
controls:1.69%
cases:2.76%
controls:0.47%
—
—
—
—
—
—
—
—
cases:3.85%
controls:0.95%
6
43
248
2497
7
12
247
2528
—
—
—
—
8
20
200
2078
mupirocin; nasal
R01AX06 [21603201]
1.4e+00
—
—
—
—
—
1.8e+00
cases:2.76%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
cases:3.85%
controls:0.67%
7
17
247
2523
—
—
—
—
—
8
14
200
2084
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
7.5e-01
6.1e-01
1.8e+00
—
—
7.2e-01
1.0e+00
cases:14.17%
controls:7.20%
cases:5.51%
controls:3.07%
cases:2.36%
controls:0.39%
—
—
—
—
cases:5.79%
controls:2.90%
cases:18.27%
controls:7.44%
36
183
218
2357
14
78
240
2462
6
10
248
2530
—
—
14
71
228
2381
38
156
170
1942
esomeprazole; oral, parenteral
A02BC05 [21600100]
8.6e-01
8.6e-01
1.3e+00
—
—
6.0e-01
3.5e-01
cases:16.54%
controls:7.72%
cases:11.02%
controls:4.96%
cases:3.54%
controls:1.02%
—
—
—
—
cases:8.26%
controls:4.69%
cases:12.98%
controls:9.49%
42
196
212
2344
28
126
226
2414
9
26
245
2514
—
—
20
115
222
2337
27
199
181
1899
Scheduled procedure
ZXD10 [2001311387]
3.5e-01
6.0e-01
—
—
—
1.7e+00
6.5e-01
cases:8.27%
controls:5.94%
cases:2.76%
controls:1.54%
—
—
—
—
—
—
cases:4.96%
controls:0.94%
cases:9.13%
controls:5.00%
21
151
233
2389
7
39
247
2501
—
—
—
12
23
230
2429
19
105
189
1993
Stress incontinence
N39.3 [45539046]
1.7e+00
—
—
—
—
—
—
cases:3.54%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
9
17
245
2523
—
—
—
—
—
—
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
1.3e-01
8.8e-01
1.7e+00
—
1.2e+00
2.5e-01
7.4e-01
cases:9.06%
controls:8.07%
cases:9.45%
controls:4.13%
cases:2.76%
controls:0.51%
—
—
cases:1.99%
controls:0.59%
cases:4.55%
controls:3.59%
cases:18.75%
controls:9.91%
23
205
231
2335
24
105
230
2435
7
13
247
2527
—
5
15
246
2520
11
88
231
2364
39
208
169
1890
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
6.1e-01
1.6e+00
—
—
—
1.5e+00
1.6e+00
cases:5.91%
controls:3.31%
cases:3.15%
controls:0.67%
—
—
—
—
—
—
cases:3.31%
controls:0.77%
cases:10.58%
controls:2.29%
15
84
239
2456
8
17
246
2523
—
—
—
8
19
234
2433
22
48
186
2050
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
3.0e-01
6.0e-01
1.5e+00
—
—
8.7e-01
7.2e-01
cases:10.24%
controls:7.80%
cases:7.87%
controls:4.49%
cases:2.36%
controls:0.55%
—
—
—
—
cases:10.74%
controls:4.81%
cases:21.63%
controls:11.87%
26
198
228
2342
20
114
234
2426
6
14
248
2526
—
—
26
118
216
2334
45
249
163
1849
Sodium and Potassium panel [Moles/volume] - Serum or Plasma
34548-8 [3045783]
-1.7e-01
9.3e-01
—
—
—
1.6e+00
8.6e-01
cases:2.36%
controls:2.80%
cases:2.76%
controls:1.10%
—
—
—
—
—
—
cases:4.13%
controls:0.90%
cases:5.77%
controls:2.53%
6
71
248
2469
7
28
247
2512
—
—
—
10
22
232
2430
12
53
196
2045
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
7.8e-01
—
—
—
—
1.6e+00
1.5e+00
cases:3.54%
controls:1.65%
—
—
—
—
—
—
—
—
cases:2.48%
controls:0.53%
cases:5.77%
controls:1.29%
9
42
245
2498
—
—
—
—
6
13
236
2439
12
27
196
2071
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
8.1e-01
9.0e-01
—
—
—
1.4e+00
1.5e+00
cases:5.51%
controls:2.52%
cases:3.15%
controls:1.30%
—
—
—
—
—
—
cases:3.72%
controls:0.98%
cases:10.58%
controls:2.53%
14
64
240
2476
8
33
246
2507
—
—
—
9
24
233
2428
22
53
186
2045
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
1.2e+00
—
—
—
—
1.2e+00
1.5e+00
cases:4.33%
controls:1.34%
—
—
—
—
—
—
—
—
cases:2.07%
controls:0.65%
cases:8.65%
controls:2.05%
11
34
243
2506
—
—
—
—
5
16
237
2436
18
43
190
2055
Body CT examination
JN4AD [2001310897]
—
—
—
—
—
1.2e+00
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:2.07%
controls:0.65%
cases:4.33%
controls:1.00%
—
—
—
—
—
5
16
237
2436
9
21
199
2077
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
1.5e+00
—
—
—
—
—
1.1e+00
cases:3.94%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:1.72%
10
24
244
2516
—
—
—
—
—
10
36
198
2062
Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
21573-1 [3003031]
7.2e-01
—
—
—
—
1.6e+00
1.4e+00
cases:4.33%
controls:2.17%
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.69%
cases:7.21%
controls:1.81%
11
55
243
2485
—
—
—
—
8
17
234
2435
15
38
193
2060
Fungus identified in Specimen by Culture
580-1 [3000494]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.21%
controls:1.86%
—
—
—
—
—
—
15
39
193
2059
Sedation and analgesia
WX002 [2001310758]
7.7e-01
—
—
—
—
—
1.4e+00
cases:5.12%
controls:2.44%
—
—
—
—
—
—
—
—
—
—
cases:5.77%
controls:1.48%
13
62
241
2478
—
—
—
—
—
12
31
196
2067
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
5.5e-01
—
—
—
—
1.4e+00
1.4e+00
cases:2.36%
controls:1.38%
—
—
—
—
—
—
—
—
cases:2.48%
controls:0.61%
cases:4.81%
controls:1.24%
6
35
248
2505
—
—
—
—
6
15
236
2437
10
26
198
2072
Medical doctor
Z2221 [2001311556]
5.4e-01
1.4e+00
—
—
—
1.2e+00
9.3e-01
cases:6.69%
controls:4.02%
cases:4.72%
controls:1.22%
—
—
—
—
—
—
cases:4.55%
controls:1.35%
cases:8.17%
controls:3.38%
17
102
237
2438
12
31
242
2509
—
—
—
11
33
231
2419
17
71
191
2027
Respiratory and circulatory monitoring
WX700 [2001310817]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.29%
controls:1.48%
—
—
—
—
—
—
11
31
197
2067
metronidazole; oral, rectal
P01AB01 [21604857]
4.4e-01
2.5e-01
—
—
—
1.3e+00
3.6e-01
cases:10.24%
controls:6.85%
cases:2.76%
controls:2.17%
—
—
—
—
—
—
cases:5.79%
controls:1.67%
cases:7.69%
controls:5.48%
26
174
228
2366
7
55
247
2485
—
—
—
14
41
228
2411
16
115
192
1983
Urinary tract infection, site not specified
N39.0 [45548665]
4.9e-01
1.2e+00
—
—
—
—
1.3e+00
cases:2.36%
controls:1.46%
cases:2.36%
controls:0.71%
—
—
—
—
—
—
—
—
cases:6.73%
controls:2.00%
6
37
248
2503
6
18
248
2522
—
—
—
—
14
42
194
2056
felodipine; oral
C08CA02 [21601748]
1.2e+00
6.7e-01
—
—
—
7.5e-01
8.8e-01
cases:5.12%
controls:1.54%
cases:2.36%
controls:1.22%
—
—
—
—
—
—
cases:2.89%
controls:1.39%
cases:4.81%
controls:2.05%
13
39
241
2501
6
31
248
2509
—
—
—
7
34
235
2418
10
43
198
2055
Fever
A03 [2002000144]
1.2e+00
—
—
—
—
—
4.6e-01
cases:4.72%
controls:1.42%
—
—
—
—
—
—
—
—
—
—
cases:2.40%
controls:1.53%
12
36
242
2504
—
—
—
—
—
5
32
203
2066
Normoblasts [#/volume] in Blood
715-3 [3021589]
8.9e-03
6.4e-01
1.2e+00
—
9.5e-01
6.0e-01
4.9e-01
cases:9.84%
controls:9.76%
cases:12.20%
controls:6.81%
cases:5.91%
controls:1.81%
—
—
cases:3.59%
controls:1.42%
cases:11.57%
controls:6.73%
cases:16.83%
controls:11.06%
25
248
229
2292
31
173
223
2367
15
46
239
2494
—
9
36
242
2499
28
165
214
2287
35
232
173
1866
Cathetrisation of vein
TPH04 [2001309597]
3.2e-01
7.4e-01
—
—
—
—
1.2e+00
cases:4.33%
controls:3.19%
cases:1.97%
controls:0.94%
—
—
—
—
—
—
—
—
cases:8.17%
controls:2.57%
11
81
243
2459
5
24
249
2516
—
—
—
—
17
54
191
2044
Caries limited to enamel
K02.0 [45576967]
5.2e-01
—
—
—
—
—
1.2e+00
cases:3.15%
controls:1.89%
—
—
—
—
—
—
—
—
—
—
cases:7.21%
controls:2.38%
8
48
246
2492
—
—
—
—
—
15
50
193
2048
ebastine; oral
R06AX22 [21603521]
1.8e-01
7.7e-01
-1.0e+50
—
—
1.2e+00
1.1e+00
cases:3.15%
controls:2.64%
cases:2.36%
controls:1.10%
cases:0.00%
controls:0.35%
—
—
—
—
cases:3.31%
controls:0.98%
cases:6.73%
controls:2.29%
8
67
246
2473
6
28
248
2512
0
9
254
2531
—
—
8
24
234
2428
14
48
194
2050
Tissue Pathology biopsy report
66121-5 [40768804]
4.7e-01
2.6e-01
—
—
—
1.1e+00
5.0e-01
cases:11.81%
controls:7.76%
cases:3.54%
controls:2.76%
—
—
—
—
—
—
cases:6.20%
controls:2.12%
cases:12.02%
controls:7.67%
30
197
224
2343
9
70
245
2470
—
—
—
15
52
227
2400
25
161
183
1937
Cardiology
6 [38004451]
2.6e-01
5.6e-01
—
—
—
1.1e+00
5.8e-01
cases:10.63%
controls:8.43%
cases:7.09%
controls:4.17%
—
—
—
—
—
—
cases:10.33%
controls:3.83%
cases:15.87%
controls:9.53%
27
214
227
2326
18
106
236
2434
—
—
—
25
94
217
2358
33
200
175
1898
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
2.8e-01
1.1e+00
—
—
—
9.0e-01
6.3e-01
cases:5.51%
controls:4.21%
cases:6.69%
controls:2.44%
—
—
—
—
—
—
cases:6.20%
controls:2.61%
cases:12.50%
controls:7.10%
14
107
240
2433
17
62
237
2478
—
—
—
15
64
227
2388
26
149
182
1949
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
2.5e-01
1.0e+00
—
—
—
4.8e-01
7.3e-01
cases:7.09%
controls:5.59%
cases:8.27%
controls:3.07%
—
—
—
—
—
—
cases:4.13%
controls:2.61%
cases:13.94%
controls:7.24%
18
142
236
2398
21
78
233
2462
—
—
—
10
64
232
2388
29
152
179
1946
General anaesthesia
WX402 [2001310806]
8.4e-01
1.0e+00
—
—
—
1.4e+00
1.0e+00
cases:5.12%
controls:2.28%
cases:3.54%
controls:1.30%
—
—
—
—
—
—
cases:3.72%
controls:0.94%
cases:7.21%
controls:2.67%
13
58
241
2482
9
33
245
2507
—
—
—
9
23
233
2429
15
56
193
2042
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
5.1e-01
1.1e+00
2.1e+00
—
—
9.1e-01
1.0e+00
cases:6.69%
controls:4.13%
cases:4.72%
controls:1.69%
cases:1.97%
controls:0.24%
—
—
—
—
cases:4.13%
controls:1.71%
cases:14.42%
controls:5.67%
17
105
237
2435
12
43
242
2497
5
6
249
2534
—
—
10
42
232
2410
30
119
178
1979
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
4.0e-01
1.3e+00
—
—
—
8.9e-01
9.8e-01
cases:4.33%
controls:2.95%
cases:3.15%
controls:0.91%
—
—
—
—
—
—
cases:3.31%
controls:1.39%
cases:8.65%
controls:3.43%
11
75
243
2465
8
23
246
2517
—
—
—
8
34
234
2418
18
72
190
2026
candesartan; oral
C09CA06 [21601829]
5.1e-01
6.0e-01
—
—
5.8e-01
9.2e-01
5.0e-01
cases:9.45%
controls:5.91%
cases:9.06%
controls:5.20%
—
—
—
—
cases:2.79%
controls:1.58%
cases:11.57%
controls:4.98%
cases:12.02%
controls:7.63%
24
150
230
2390
23
132
231
2408
—
—
7
40
244
2495
28
122
214
2330
25
160
183
1938
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
2.7e-01
9.1e-01
6.9e-01
—
1.1e+00
6.5e-01
5.1e-01
cases:15.35%
controls:12.20%
cases:16.93%
controls:7.60%
cases:3.54%
controls:1.81%
—
—
cases:3.59%
controls:1.26%
cases:13.22%
controls:7.34%
cases:22.12%
controls:14.59%
39
310
215
2230
43
193
211
2347
9
46
245
2494
—
9
32
242
2503
32
180
210
2272
46
306
162
1792
Inpatient Visit
IP [9201]
4.1e-01
1.5e-02
—
—
-1.0e+50
9.5e-01
8.8e-01
cases:8.66%
controls:5.91%
cases:2.76%
controls:2.72%
—
—
—
—
cases:0.00%
controls:0.28%
cases:5.79%
controls:2.32%
cases:12.02%
controls:5.34%
22
150
232
2390
7
69
247
2471
—
—
0
7
251
2528
14
57
228
2395
25
112
183
1986
Other specified counselling
Z71.8 [45581061]
3.6e-01
9.7e-01
—
—
—
6.0e-01
8.7e-01
cases:6.30%
controls:4.49%
cases:4.72%
controls:1.85%
—
—
—
—
—
—
cases:3.31%
controls:1.84%
cases:12.50%
controls:5.67%
16
114
238
2426
12
47
242
2493
—
—
—
8
45
234
2407
26
119
182
1979
ispaghula (psylla seeds); oral
A06AC01 [21600555]
2.6e-01
—
—
—
—
6.6e-01
8.6e-01
cases:5.51%
controls:4.29%
—
—
—
—
—
—
—
—
cases:4.55%
controls:2.41%
cases:11.06%
controls:5.00%
14
109
240
2431
—
—
—
—
11
59
231
2393
23
105
185
1993
Demanding periodontal treatment
SDA04 [2001310329]
3.2e-01
—
-1.0e+50
—
—
3.8e-01
8.5e-01
cases:5.51%
controls:4.06%
—
—
cases:0.00%
controls:0.28%
—
—
—
—
cases:2.07%
controls:1.43%
cases:10.58%
controls:4.81%
14
103
240
2437
—
0
7
254
2533
—
—
5
35
237
2417
22
101
186
1997
Bacteria identified in Urine by Culture
630-4 [3026008]
3.2e-01
-1.5e-01
—
—
—
3.6e-01
8.4e-01
cases:6.69%
controls:4.96%
cases:1.97%
controls:2.28%
—
—
—
—
—
—
cases:3.31%
controls:2.32%
cases:13.94%
controls:6.53%
17
126
237
2414
5
58
249
2482
—
—
—
8
57
234
2395
29
137
179
1961
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
2.0e-01
8.3e-01
9.0e-01
—
1.2e+00
5.6e-01
4.9e-01
cases:11.81%
controls:9.84%
cases:11.42%
controls:5.31%
cases:2.76%
controls:1.14%
—
—
cases:2.79%
controls:0.83%
cases:9.92%
controls:5.91%
cases:17.31%
controls:11.39%
30
250
224
2290
29
135
225
2405
7
29
247
2511
—
7
21
244
2514
24
145
218
2307
36
239
172
1859
Monocytes/Leukocytes in Blood
26485-3 [3019069]
2.0e-01
8.3e-01
9.0e-01
—
1.3e+00
6.1e-01
4.7e-01
cases:11.81%
controls:9.88%
cases:11.42%
controls:5.31%
cases:2.76%
controls:1.14%
—
—
cases:2.79%
controls:0.79%
cases:10.33%
controls:5.91%
cases:17.31%
controls:11.53%
30
251
224
2289
29
135
225
2405
7
29
247
2511
—
7
20
244
2515
25
145
217
2307
36
242
172
1856
losartan; oral
C09CA01 [21601824]
5.1e-01
4.4e-01
—
—
—
1.5e-01
8.2e-01
cases:8.27%
controls:5.12%
cases:7.09%
controls:4.69%
—
—
—
—
—
—
cases:6.20%
controls:5.38%
cases:14.42%
controls:6.91%
21
130
233
2410
18
119
236
2421
—
—
—
15
132
227
2320
30
145
178
1953
codeine and paracetamol
N02AJ06 [1123647]
3.4e-01
3.2e-01
—
—
—
8.2e-01
4.0e-01
cases:17.32%
controls:12.95%
cases:7.09%
controls:5.24%
—
—
—
—
—
—
cases:10.74%
controls:5.06%
cases:17.79%
controls:12.63%
44
329
210
2211
18
133
236
2407
—
—
—
26
124
216
2328
37
265
171
1833
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
1.4e-01
8.1e-01
9.7e-01
—
1.1e+00
6.2e-01
5.1e-01
cases:11.42%
controls:10.08%
cases:11.02%
controls:5.24%
cases:2.76%
controls:1.06%
—
—
cases:2.39%
controls:0.79%
cases:9.92%
controls:5.59%
cases:18.27%
controls:11.82%
29
256
225
2284
28
133
226
2407
7
27
247
2513
—
6
20
245
2515
24
137
218
2315
38
248
170
1850
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
1.7e-01
7.9e-01
8.3e-01
—
1.2e+00
5.8e-01
4.4e-01
cases:11.81%
controls:10.16%
cases:11.42%
controls:5.55%
cases:2.76%
controls:1.22%
—
—
cases:2.79%
controls:0.83%
cases:10.33%
controls:6.08%
cases:17.31%
controls:11.92%
30
258
224
2282
29
141
225
2399
7
31
247
2509
—
7
21
244
2514
25
149
217
2303
36
250
172
1848
Basophils/Leukocytes in Blood
30180-4 [3022096]
2.0e-01
7.8e-01
9.0e-01
—
1.2e+00
6.1e-01
4.8e-01
cases:11.81%
controls:9.84%
cases:11.02%
controls:5.35%
cases:2.76%
controls:1.14%
—
—
cases:2.79%
controls:0.83%
cases:10.33%
controls:5.91%
cases:17.31%
controls:11.49%
30
250
224
2290
28
136
226
2404
7
29
247
2511
—
7
21
244
2514
25
145
217
2307
36
241
172
1857
amlodipine; oral
C08CA01 [21601747]
4.6e-01
6.3e-01
9.2e-02
—
5.4e-01
6.7e-01
7.6e-01
cases:14.17%
controls:9.45%
cases:13.39%
controls:7.60%
cases:2.76%
controls:2.52%
—
—
cases:3.59%
controls:2.13%
cases:13.64%
controls:7.46%
cases:21.15%
controls:11.15%
36
240
218
2300
34
193
220
2347
7
64
247
2476
—
9
54
242
2481
33
183
209
2269
44
234
164
1864
12 lead EKG panel
34534-8 [3044889]
3.0e-01
5.2e-01
1.3e+00
—
—
4.4e-01
7.2e-01
cases:20.08%
controls:15.67%
cases:13.78%
controls:8.66%
cases:2.36%
controls:0.67%
—
—
—
—
cases:10.33%
controls:6.93%
cases:32.21%
controls:18.73%
51
398
203
2142
35
220
219
2320
6
17
248
2523
—
—
25
170
217
2282
67
393
141
1705
calcium (different salts in combination); oral
A12AA20 [21600872]
4.7e-01
4.5e-01
3.9e-01
—
—
5.1e-01
7.0e-01
cases:14.17%
controls:9.33%
cases:10.24%
controls:6.77%
cases:2.36%
controls:1.61%
—
—
—
—
cases:10.74%
controls:6.73%
cases:17.79%
controls:9.72%
36
237
218
2303
26
172
228
2368
6
41
248
2499
—
—
26
165
216
2287
37
204
171
1894
Creatinine [Moles/volume] in Urine
14683-7 [3009508]
1.8e-01
6.1e-01
—
—
—
5.2e-01
6.6e-01
cases:7.09%
controls:5.98%
cases:7.48%
controls:4.21%
—
—
—
—
—
—
cases:7.02%
controls:4.28%
cases:17.31%
controls:9.72%
18
152
236
2388
19
107
235
2433
—
—
—
17
105
225
2347
36
204
172
1894
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
1.9e-01
5.3e-01
0.0e+00
—
5.0e-01
5.2e-01
3.0e-01
cases:35.83%
controls:31.54%
cases:25.20%
controls:16.57%
cases:3.54%
controls:3.54%
—
—
cases:4.78%
controls:2.96%
cases:26.03%
controls:17.37%
cases:44.23%
controls:36.99%
91
801
163
1739
64
421
190
2119
9
90
245
2450
—
12
75
239
2460
63
426
179
2026
92
776
116
1322
Counselling and guidance related to occupational health
SPAT1311 [2001700412]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
254
2530
—
—
—
—
—
—
budesonide; inhalant
R03BA02 [21603285]
-1.4e-01
2.2e-01
—
—
—
-9.2e-03
4.2e-02
cases:5.51%
controls:6.26%
cases:4.33%
controls:3.50%
—
—
—
—
—
—
cases:3.72%
controls:3.75%
cases:6.25%
controls:6.01%
14
159
240
2381
11
89
243
2451
—
—
—
9
92
233
2360
13
126
195
1972
Thorax and upper abdomen combined extensive CT examination of
GD5BD [2001303656]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
0
5
208
2093
Low pressure glaucoma
H40.11 [2000502333]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.40%
controls:0.48%
—
—
—
—
—
—
5
10
203
2088
Cells panel - Urine sediment
58434-2 [40761535]
3.1e-01
1.6e+00
—
—
—
—
1.1e+00
cases:1.97%
controls:1.46%
cases:2.76%
controls:0.59%
—
—
—
—
—
—
—
—
cases:5.29%
controls:1.81%
5
37
249
2503
7
15
247
2525
—
—
—
—
11
38
197
2060
Office Visit
OMOP4822458 [581477]
4.2e-01
8.1e-01
—
—
—
6.2e-01
3.1e-01
cases:10.24%
controls:6.97%
cases:4.33%
controls:1.97%
—
—
—
—
—
—
cases:3.72%
controls:2.04%
cases:9.13%
controls:6.86%
26
177
228
2363
11
50
243
2490
—
—
—
9
50
233
2402
19
144
189
1954
Mixed conductive and sensorineural hearing loss, bilateral
H90.6 [45601013]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
0
8
254
2532
—
—
—
—
—
0
6
208
2092
Erythrocytes [#/volume] in Cerebral spinal fluid
26454-9 [3027475]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
0
8
254
2532
—
—
—
—
—
0
5
208
2093
Anion gap in Blood by calculation
41276-7 [3039000]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
254
2534
—
—
—
—
—
—
methenamine; oral
J01XX05 [21603065]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
cases:0.00%
controls:0.52%
—
—
—
—
—
0
5
242
2447
0
11
208
2087
Corn/callosity
S20 [2002000985]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
0
8
254
2532
—
—
—
—
0
5
242
2447
—
Fracture: radius/ulna
L72 [2002000691]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
254
2535
—
—
—
—
—
—
Malignant tumor of the rectum without histology
C20.90 [2000500573]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
254
2535
—
—
—
—
—
—
chlorhexidine
D09AA12 [21602275]
—
—
—
—
—
—
1.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.40%
controls:2.05%
—
—
—
—
—
—
5
43
203
2055
Hypertension secondary to other renal disorders
I15.1 [45557535]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:2.48%
controls:0.00%
—
—
—
—
—
—
—
6
0
236
2452
—
First degree haemorrhoids
K64.0 [45548166]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
254
2535
—
—
—
—
—
—
Varicose veins of lower extremities with ulcer
I83.0 [45557601]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
0
6
254
2534
—
—
—
—
—
0
5
208
2093
Bicipital tendinitis
M75.2 [45557984]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
254
2535
—
—
—
—
—
—
Reaction to severe stress, unspecified
F43.9 [45552484]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
0
7
254
2533
—
—
—
—
—
0
5
208
2093
mometasone, combinations
R01AD59 [947911]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
0
8
242
2444
—
Vacuum extractor delivery
O81.4 [45582577]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
254
2534
—
—
—
—
—
—
Leukocytes [#/volume] in Pleural fluid
26467-1 [3023199]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
0
5
208
2093
Maternal care for breech presentation
O32.1 [45606580]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
254
2535
—
—
—
—
—
—
Skin colour change
S08 [2002000973]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
11
208
2087
formoterol and fluticasone
R03AK11 [44819166]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.28%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
0
7
254
2533
0
6
254
2534
—
—
—
—
—
Urination problems other
U05 [2002001140]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
254
2533
—
—
—
—
—
—
Restoration involving the entire crown of the tooth
SFA40 [2001310361]
—
—
—
—
—
—
-6.6e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.85%
controls:4.10%
—
—
—
—
—
—
8
86
200
2012
Limited function/disability NOS
A28 [2002000162]
—
—
—
—
-1.0e+50
—
1.5e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
cases:3.37%
controls:2.91%
—
—
—
—
0
5
251
2530
—
7
61
201
2037
cefaclor; oral
J01DC04 [21602886]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
254
2527
—
—
—
—
—
—
Cystic disease of liver
Q44.6 [45553680]
—
1.0e+50
—
1.0e+50
1.0e+50
1.0e+50
1.0e+50
—
—
cases:2.36%
controls:0.00%
—
—
cases:100.00%
controls:0.00%
cases:14.74%
controls:0.00%
cases:46.28%
controls:0.00%
cases:50.48%
controls:0.00%
—
6
0
248
2540
—
254
0
0
2540
37
0
214
2535
112
0
130
2452
105
0
103
2098
Incontinence urine
U04 [2002001139]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
17
208
2081
Catheterisation instruction
TKC22 [2001306021]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
254
2534
—
—
—
—
—
—
ergotamine, combinations with psycholeptics; oral
N02CA72 [21604372]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
254
2535
—
—
—
—
—
—
Pustulosis palmaris et plantaris
L40.3 [45591634]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
0
6
208
2092
Senile macular degeneration (atrophic)(exudative)
H35.31 [2000502315]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
6
254
2534
—
—
—
—
—
0
8
208
2090
Respiratory symptom/complaint other
R29 [2002000898]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.47%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
0
12
254
2528
0
7
254
2533
—
—
—
—
—
Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection
40988-8 [3044254]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
19
254
2521
—
—
—
—
—
—
clopidogrel; oral
B01AC04 [21600989]
6.2e-01
7.4e-01
—
—
—
8.4e-01
5.6e-01
cases:3.54%
controls:1.93%
cases:2.76%
controls:1.34%
—
—
—
—
—
—
cases:2.89%
controls:1.26%
cases:4.33%
controls:2.53%
9
49
245
2491
7
34
247
2506
—
—
—
7
31
235
2421
9
53
199
2045
Cat dander IgE Ab [Units/volume] in Serum
6833-8 [3023430]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
0
5
208
2093
fluticasone furoate; nasal
R01AD12 [21605053]
4.4e-01
6.2e-01
-1.0e+50
—
—
5.2e-01
5.2e-01
cases:12.60%
controls:8.46%
cases:7.09%
controls:3.94%
cases:0.00%
controls:0.63%
—
—
—
—
cases:5.37%
controls:3.26%
cases:12.50%
controls:7.82%
32
215
222
2325
18
100
236
2440
0
16
254
2524
—
—
13
80
229
2372
26
164
182
1934
Other and unspecified ventral hernia without obstruction or gangrene
K43.9 [45533594]
1.6e+00
—
—
—
—
—
—
cases:1.97%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
5
10
249
2530
—
—
—
—
—
—
salbutamol; oral, parenteral
R03CC02 [21603312]
7.1e-02
—
—
—
—
—
—
cases:2.36%
controls:2.20%
—
—
—
—
—
—
—
—
—
—
—
—
6
56
248
2484
—
—
—
—
—
—
Malignant tumor of the lower inner quadrant of the mammary gland, ductal tumor
C50.31 [2000500998]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
cases:0.00%
controls:0.20%
cases:0.00%
controls:0.43%
—
0
5
254
2535
—
—
—
0
5
242
2447
0
9
208
2089
Monitoring of normal pregnancy
SPAT1196 [2001700297]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
254
2526
—
—
—
—
—
—
Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2865-4 [3015322]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.88%
controls:0.48%
—
—
—
—
—
—
6
10
202
2088
Hand/finger symptom/complaint
L12 [2002000636]
2.0e-01
—
—
—
—
—
1.2e-01
cases:1.97%
controls:1.61%
—
—
—
—
—
—
—
—
—
—
cases:2.88%
controls:2.57%
5
41
249
2499
—
—
—
—
—
6
54
202
2044
Three-surface restoration
SFA30 [2001310360]
8.2e-02
2.9e-01
—
—
-1.0e+50
—
4.2e-02
cases:7.48%
controls:6.93%
cases:3.54%
controls:2.68%
—
—
—
—
cases:0.00%
controls:0.20%
—
—
cases:10.10%
controls:9.72%
19
176
235
2364
9
68
245
2472
—
—
0
5
251
2530
—
21
204
187
1894
clotrimazole; vaginal
G01AF02 [21602393]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
254
2533
—
—
—
—
—
—
Fracture of upper end of humerus
S42.2 [45544677]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
254
2531
—
—
—
—
—
—
formoterol and budesonide
R03AK07 [21603281]
3.9e-01
—
—
—
—
—
5.3e-01
cases:2.36%
controls:1.61%
—
—
—
—
—
—
—
—
—
—
cases:3.37%
controls:2.00%
6
41
248
2499
—
—
—
—
—
7
42
201
2056
Other secondary gonarthrosis
M17.5 [45577166]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
0
5
208
2093
General and Unspecified, Blood test
A34 [2002000168]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
0
5
208
2093
Assessment of adjustments needed in living environment
SPAT1231 [2001700332]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
7
208
2091
Sicca syndrome [Sjögren]
M35.0 [45562711]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
cases:0.00%
controls:0.29%
cases:0.00%
controls:0.62%
—
0
8
254
2532
—
—
—
0
7
242
2445
0
13
208
2085
Endometriosis, unspecified
N80.9 [45543892]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
0
5
208
2093
Fracture of patella
S82.0 [45598719]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
0
5
208
2093
Social phobias
F40.1 [45595907]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
254
2535
—
—
—
—
—
—
Second degree haemorrhoids
K64.1 [45572223]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
0
6
208
2092
palonosetron, combinations
A04AA55 [45893275]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
254
2532
—
—
—
—
—
—
Blasts/Leukocytes in Blood
26446-5 [3025159]
—
1.3e+00
—
—
—
—
4.2e-01
—
—
cases:3.54%
controls:1.02%
—
—
—
—
—
—
—
—
cases:2.88%
controls:1.91%
—
9
26
245
2514
—
—
—
—
6
40
202
2058
boric acid
S02AA03 [21605149]
7.7e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:2.36%
controls:1.10%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
6
28
248
2512
0
9
254
2531
—
—
—
0
7
242
2445
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
49
35
17.09
55.14
2.0
2.3
3.12
108.75
u/ml
0.49
49
35
54
73
9.12
39.37
8.6
3.1
1.91
1.48
mg/l
1.79
54
63
102
277
5.47
37.24
11.7
2.8
6.00
7.41
umol/l
0.64
96
247
211
1063
6.71
35.07
16.1
4.6
35.81
35.86
g/l
0.05
203
1005
40
43
10.85
34.50
1.8
1.3
—
—
—
0
0
38
38
11.58
34.45
1.7
1.1
284.84
295.56
u/ml
0.04
32
18
106
315
5.05
34.38
21.2
5.8
1.13
1.04
mmol/l
2.04
99
289
38
40
10.99
33.23
1.9
1.1
167.57
170.60
au/ml
0.05
14
14
61
115
6.66
32.72
2.9
3.3
235.33
2108.83
u/ml
0.86
54
99
61
133
5.71
27.88
12.7
4.0
23.36
24.38
mmol/l
2.02
61
133
200
1090
4.87
26.63
18.7
12.4
1.18
1.20
inr
0.17
167
892
71
188
4.85
25.77
19.4
8.6
—
—
—
0
0
40
62
7.47
25.55
1.6
1.2
—
—
—
0
0
34
18
21.58
23.32
1.2
1.2
—
—
—
0
0
74
233
4.07
21.06
13.1
4.0
7.36
7.39
ph
3.56
52
134
72
228
4.01
20.26
3.1
1.5
—
—
—
0
0
150
762
3.35
20.00
14.5
4.4
7.39
7.40
ph
1.67
120
527
149
768
3.26
19.12
5.0
2.6
63.76
70.00
u/l
0.32
142
712
26
15
19.14
17.34
3.6
1.1
—
—
—
0
0
76
276
3.50
17.19
3.2
1.5
—
—
—
0
0
23
10
25.11
16.75
6.0
3.0
0.57
0.60
mmol/l
—
23
10
191
1201
3.35
16.35
22.7
7.1
1.20
1.22
mmol/l
1.40
172
1032
25
38
7.19
16.06
1.8
1.1
—
—
—
0
0
20
6
35.97
15.99
1.1
1.0
—
—
—
0
0
80
313
3.27
15.92
3.1
1.7
—
—
—
0
0
179
1094
3.13
15.91
20.2
6.3
1.21
1.22
mmol/l
0.44
171
1002
19
5
40.81
15.61
1.1
1.0
—
—
—
0
0
74
282
3.29
15.32
2.9
4.5
3.73
24.83
ug/l
0.81
52
236
65
229
3.47
15.26
6.4
2.4
40.53
32.23
u/l
0.78
58
186
50
148
3.96
15.18
2.0
1.4
—
—
—
0
0
121
613
2.85
15.03
10.2
4.0
—
—
—
0
0
48
149
3.74
13.55
15.7
8.3
24.15
25.09
mmol/l
1.35
48
149
22
19
12.55
12.58
1.2
1.2
—
—
—
0
0
115
616
2.58
12.18
6.5
2.9
349.16
336.79
umol/l
0.64
107
539
74
319
2.86
12.05
14.7
6.6
104.11
104.05
mmol/l
0.03
74
319
111
588
2.57
12.00
3.1
2.3
2.47
3.07
mg/l
2.33
95
507
167
1075
2.60
11.86
4.6
2.7
—
—
estimate
—
0
0
16
7
24.25
11.72
2.2
1.7
—
—
—
0
0
130
753
2.48
11.47
4.1
2.3
—
—
—
0
0
109
583
2.52
11.43
7.4
3.9
—
0.17
—
0
6
168
1102
2.54
11.18
4.3
2.5
81.88
79.16
nmol/l
0.73
159
987
210
1539
3.07
11.12
10.9
3.3
83.62
46.79
u/l
3.85
202
1448
26
61
4.63
10.58
9.7
3.2
82.12
57.96
%
8.78
26
61
15
8
19.82
10.39
1.1
1.1
—
—
—
0
0
14
6
24.56
10.35
1.1
1.2
—
—
—
0
0
117
670
2.38
10.30
8.9
3.2
0.13
0.40
e6/l
2.65
95
474
71
327
2.62
9.98
3.0
2.0
—
—
—
0
0
130
789
2.32
9.90
9.2
3.3
13.43
121.18
e6/l
0.71
107
598
174
1203
2.41
9.66
12.8
6.2
0.53
0.57
e9/l
1.48
151
1018
78
382
2.50
9.61
6.0
3.0
1.15
2.97
e6/l
2.04
48
184
176
1226
2.41
9.56
12.8
6.3
1.59
1.86
e9/l
2.47
154
1074
181
1278
2.43
9.50
7.5
4.0
0.00
0.00
estimate
-0.00
42
275
22
49
4.82
9.50
10.5
2.7
83.59
57.87
%
8.68
22
49
174
1209
2.38
9.46
12.8
6.2
0.04
0.04
e9/l
1.50
151
1018
153
1014
2.27
9.20
6.6
3.6
6.24
6.18
ph
0.29
86
580
181
1289
2.39
9.15
7.5
4.0
0.00
5.72
estimate
0.50
40
284
177
1249
2.36
9.13
13.0
6.6
0.18
0.18
e9/l
0.07
156
1079
186
1342
2.43
9.10
15.3
9.9
4.18
3.97
e9/l
0.54
167
1163
182
1301
2.39
9.09
7.6
4.1
0.00
0.00
estimate
-0.00
42
261
139
891
2.23
9.01
11.1
4.1
50.40
84.40
e6/l
0.54
112
620
160
1093
2.25
8.77
6.4
3.1
139.07
112.17
ug/l
1.29
152
1016
126
789
2.18
8.51
13.0
6.0
—
—
—
0
0
67
325
2.44
8.30
1.4
1.3
—
—
—
0
0
59
272
2.52
8.14
4.1
3.4
1.74
1.77
%
0.07
52
248
159
1104
2.17
8.09
13.2
6.2
0.65
0.69
%
0.46
150
1019
116
714
2.15
8.08
9.6
6.6
—
—
—
0
0
29
90
3.51
8.08
3.7
2.5
20.62
20.83
s
0.08
29
83
159
1106
2.16
8.03
13.2
6.2
2.88
2.78
%
0.21
149
1022
159
1106
2.16
8.03
13.0
6.2
60.42
57.83
%
2.10
152
1042
159
1108
2.16
7.96
13.3
6.3
8.51
8.87
%
0.85
150
1028
50
216
2.64
7.86
4.7
3.2
58.20
69.95
e9/l
1.56
29
156
160
1128
2.12
7.64
13.3
6.3
25.10
27.39
%
1.92
151
1056
55
253
2.50
7.59
13.6
7.3
7.40
7.42
ph
1.07
24
153
54
252
2.45
7.20
13.6
7.3
-0.11
1.00
mmol/l
2.10
48
220
80
445
2.16
7.06
3.7
3.9
465.38
211.93
ng/l
0.40
69
345
26
84
3.33
6.81
2.0
3.8
1.32
2.18
ratio
0.65
11
46
27
92
3.16
6.49
2.1
4.2
1740.91
105.18
mg/l
0.47
21
82
27
92
3.16
6.49
2.1
4.2
49.55
31.05
mg/l
0.85
21
82
38
159
2.63
6.32
2.6
1.8
1.10
1.42
g/l
0.67
38
147
113
738
1.95
6.29
4.0
3.1
—
—
—
0
0
145
1041
1.91
5.97
22.9
12.1
0.00
0.00
e9/l
0.41
119
848
126
867
1.90
5.88
5.1
3.5
2.34
2.36
mmol/l
0.91
119
787
98
621
1.94
5.87
1.6
1.4
—
—
—
0
0
246
2222
4.03
5.86
42.1
15.6
22.65
22.54
mg/l
0.02
229
1806
62
337
2.11
5.68
1.4
1.2
—
—
—
0
0
9
8
11.60
5.33
1.2
1.0
1712.22
1253.25
miu/ml
—
9
8
20
64
3.31
5.32
3.6
2.9
2.69
1.55
index
0.36
13
33
119
827
1.82
5.20
6.5
4.0
5.87
8.75
mg/mmol
0.81
94
481
22
76
3.07
5.18
4.0
1.2
0.89
0.90
g/l
0.05
22
76
13
23
5.90
5.13
3.9
3.6
11.68
11.16
%
0.14
13
23
31
133
2.52
4.89
10.4
2.7
1.25
1.22
%
0.05
31
133
143
1065
1.78
4.84
2.5
2.1
94.03
97.58
pmol/l
0.48
82
529
45
229
2.17
4.83
1.9
1.4
—
—
—
0
0
115
804
1.78
4.83
5.9
3.4
37.24
47.42
mg/l
0.40
94
494
26
103
2.70
4.80
2.1
1.4
0.21
0.30
mg/l
—
8
40
107
735
1.79
4.75
2.0
1.7
20.34
21.74
nmol/l
0.48
95
616
54
298
2.03
4.69
1.8
1.4
—
—
—
0
0
38
184
2.25
4.60
1.9
2.4
—
—
—
0
0
7
5
14.34
4.60
1.9
1.0
—
—
—
0
0
17
54
3.30
4.57
8.9
2.5
11.15
9.17
pmol/l
0.22
17
54
30
132
2.44
4.50
10.6
2.7
0.71
0.60
%
0.53
30
132
117
839
1.73
4.38
6.0
3.2
6.75
7.41
mmol/l
0.98
107
687
85
557
1.79
4.36
6.5
4.0
1.02
1.02
kg/l
0.63
64
360
103
732
1.68
3.87
8.0
4.1
0.00
0.00
estimate
-0.00
39
262
128
965
1.66
3.82
2.8
2.2
—
—
—
0
0
6
6
10.20
3.51
1.7
1.2
—
—
—
0
0
61
385
1.77
3.47
1.9
1.7
1129.19
1204.57
nmol/l
0.33
51
284
13
43
3.13
3.30
1.0
1.0
—
—
—
0
0
126
973
1.58
3.24
7.2
3.9
0.00
0.01
estimate
0.80
37
230
55
344
1.76
3.21
1.6
1.4
234.29
618.88
titre
—
7
89
7
11
6.51
3.20
2.0
2.0
134.79
63.75
ug/l
—
7
11
16
61
2.73
3.20
1.3
1.6
—
—
—
0
0
9
20
4.62
3.14
1.2
3.0
3.69
3.08
nmol/l
—
9
20
12
36
3.45
3.06
1.0
1.0
—
—
—
0
0
75
524
1.61
2.88
3.7
2.6
2.45
2.45
mmol/l
0.12
70
473
26
134
2.05
2.72
1.4
1.2
—
—
—
0
0
6
10
6.11
2.71
1.5
2.6
3.83
4.29
ug/l
—
6
10
12
41
3.02
2.66
4.1
2.6
3.26
4.91
e9/l
2.06
12
41
133
1072
1.50
2.63
2.6
2.0
1.10
1.33
mmol/l
5.92
112
895
6
11
5.56
2.56
3.8
2.9
1.00
0.64
index
—
6
11
243
2273
2.47
2.53
31.3
13.8
—
—
—
0
0
10
32
3.21
2.46
2.1
1.1
—
—
—
0
0
47
303
1.68
2.45
2.9
2.2
138.05
123.73
ug/g
0.15
40
236
96
734
1.49
2.41
1.9
2.1
132.21
178.86
u/l
0.71
91
693
9
28
3.29
2.33
1.0
2.7
—
—
—
0
0
8
23
3.56
2.29
1.1
1.2
—
—
—
0
0
6
13
4.70
2.28
1.0
1.6
—
—
—
0
0
38
236
1.72
2.27
1.4
1.5
—
—
—
0
0
20
102
2.04
2.17
2.5
1.9
—
—
—
0
0
8
25
3.27
2.11
1.1
1.4
—
—
—
0
0
23
125
1.92
2.10
2.2
1.6
—
—
—
0
0
45
301
1.60
2.04
2.3
3.2
4.44
5.46
e9/l
0.45
39
264
17
84
2.10
2.01
2.1
2.0
145.59
314.23
ug/l
1.26
17
79
15
71
2.18
1.96
6.0
3.1
7.41
7.41
ph
0.49
15
71
38
246
1.64
1.96
2.0
1.7
—
—
—
0
0
0
53
0.00
1.89
0.0
4.6
—
23.45
—
0
38
11
46
2.45
1.88
9.3
2.6
—
—
—
0
0
6
17
3.59
1.85
5.3
2.9
814.67
595.30
ml
—
6
10
69
518
1.46
1.84
1.8
1.4
2.57
2.35
g/l
0.37
48
295
71
536
1.45
1.84
2.4
1.8
1.79
1.28
mg/l
0.82
55
435
249
2400
2.59
1.84
57.1
24.2
6.48
6.53
e9/l
0.16
244
2352
22
124
1.85
1.82
3.4
2.1
0.00
0.02
estimate
—
7
43
11
47
2.40
1.80
6.9
3.0
8.75
8.66
kpa
0.04
11
47
11
47
2.40
1.80
6.9
3.0
4.94
5.07
kpa
0.30
11
47
14
67
2.15
1.79
1.5
1.3
105.40
300.58
miu/ml
—
5
31
31
195
1.67
1.79
8.6
4.0
—
—
—
0
0
7
24
2.97
1.73
1.7
2.0
91.11
89.46
%
—
7
24
234
2202
1.76
1.72
7.1
5.4
5.72
5.96
mmol/l
2.65
220
2044
34
222
1.61
1.71
5.7
4.1
0.86
1.00
%
0.17
14
67
6
19
3.21
1.67
4.7
2.6
15.00
13.82
index
—
6
11
6
19
3.21
1.67
1.0
3.6
1188.67
1091.26
mg
—
6
19
32
208
1.62
1.64
5.2
3.9
0.69
0.62
%
0.08
13
55
32
208
1.62
1.64
5.8
4.5
0.00
0.11
%
—
10
47
5
14
3.62
1.62
1.0
1.0
—
—
—
0
0
5
14
3.62
1.62
5.8
2.6
474.80
493.89
min
—
5
9
109
903
1.36
1.62
3.2
3.8
73.99
92.13
ng/l
0.08
79
651
6
20
3.05
1.59
1.0
1.3
—
—
—
0
0
71
554
1.39
1.51
7.5
5.2
—
—
—
0
0
12
59
2.08
1.46
4.8
2.4
57.17
60.90
%
0.54
12
59
18
103
1.80
1.45
1.4
1.6
—
—
—
0
0
6
22
2.77
1.44
1.7
1.5
23.73
37.57
ng/l
—
6
22
15
81
1.91
1.43
1.5
1.3
191.33
309.54
ug/g
—
9
47
230
2175
1.59
1.38
9.0
6.7
37.78
39.33
mmol/mol
2.73
222
2040
6
135
0.43
1.31
1.3
2.3
12.40
13.24
nmol/l
—
6
128
236
2250
1.66
1.31
7.2
5.4
4.51
4.72
mmol/l
2.78
224
2096
5
18
2.81
1.29
7.8
1.2
28.90
21.16
umol/l
—
5
10
238
2279
1.66
1.22
8.0
6.2
2.58
2.75
mmol/l
2.52
223
2115
34
241
1.47
1.22
4.2
2.0
0.00
0.06
estimate
—
6
52
30
210
1.49
1.15
6.0
4.2
0.40
0.20
%
—
10
55
19
120
1.63
1.12
2.2
2.3
—
—
—
0
0
5
21
2.41
1.09
3.6
2.5
—
—
—
0
0
84
706
1.28
1.06
5.4
3.4
0.00
0.00
estimate
-0.00
36
225
11
60
1.87
1.04
1.7
1.2
—
—
—
0
0
7
35
2.03
1.01
1.0
1.3
—
—
—
0
0
7
35
2.03
1.01
1.0
1.3
—
—
—
0
0
7
35
2.03
1.01
1.0
1.3
—
—
—
0
0
7
35
2.03
1.01
1.0
1.3
—
—
—
0
0
14
84
1.71
1.00
4.9
2.9
141.22
290.37
mg/l
—
9
30
5
23
2.20
0.98
1.4
1.7
6.58
4.33
mg/l
—
5
23
0
30
0.00
0.98
0.0
1.7
—
—
—
0
0
11
62
1.81
0.95
1.4
1.7
5.20
4.48
iu/l
—
6
29
6
27
2.25
0.94
2.7
1.2
95.33
101.11
pmol/l
—
6
27
222
2118
1.37
0.92
5.8
5.8
1.94
1.92
mu/l
0.09
211
1955
8
42
1.93
0.89
2.3
1.3
—
—
—
0
0
15
96
1.60
0.86
5.1
3.2
—
—
—
0
0
194
1831
1.25
0.78
4.7
4.6
15.24
14.81
pmol/l
1.74
186
1681
6
34
1.78
0.77
2.7
1.2
—
—
—
0
0
16
108
1.51
0.75
1.3
1.2
—
—
—
0
0
5
25
2.02
0.73
3.6
1.9
—
—
—
0
0
13
86
1.54
0.67
2.2
3.1
—
—
—
0
0
231
2243
1.32
0.59
7.2
5.3
1.53
1.52
mmol/l
0.10
216
2077
6
35
1.73
0.58
2.3
1.9
—
—
—
0
0
44
515
0.82
0.52
1.5
1.3
12.29
37.13
iu/ml
—
10
167
56
493
1.17
0.45
1.6
1.8
499.98
28058009.10
pmol/l
0.50
48
417
16
207
0.76
0.44
1.6
1.4
—
—
—
0
0
15
113
1.35
0.43
1.5
1.6
20.80
4.75
iu/ml
—
5
28
220
2141
1.20
0.42
5.9
4.5
1.12
1.27
mmol/l
4.98
203
1971
22
177
1.27
0.42
1.4
1.2
56.42
150.96
u/ml
—
9
69
5
33
1.53
0.41
1.4
1.2
—
—
—
0
0
0
15
0.00
0.41
0.0
1.7
—
72.13
—
0
15
0
16
0.00
0.41
0.0
1.1
—
0.45
—
0
8
0
18
0.00
0.40
0.0
1.9
—
7.63
—
0
18
83
901
0.88
0.38
3.6
3.4
—
—
—
0
0
5
36
1.40
0.38
1.8
2.1
32.00
31.50
pg
—
5
36
37
321
1.18
0.36
1.4
1.3
—
—
—
0
0
6
41
1.47
0.36
1.0
1.1
—
—
—
0
0
6
41
1.47
0.36
1.0
1.1
—
—
—
0
0
64
580
1.14
0.36
1.4
1.2
4.72
1.46
u/ml
0.44
12
169
20
167
1.21
0.29
1.3
1.3
—
—
—
0
0
36
318
1.15
0.29
4.0
3.2
0.96
0.78
ug/l
0.52
26
206
11
85
1.31
0.28
1.3
1.1
—
—
—
0
0
19
159
1.21
0.27
1.7
2.0
3.54
3.48
mmol/l
—
10
120
18
214
0.83
0.27
4.8
2.4
6.05
6.11
ph
—
10
142
5
72
0.69
0.26
1.0
1.2
1.64
1.58
g/l
—
5
72
5
38
1.32
0.23
2.2
1.2
—
—
nmol/l
—
0
0
5
41
1.22
0.22
3.0
2.1
0.70
0.87
%
—
5
26
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
4.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
0.00
—
0
10
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
0.09
—
0
7
24
213
1.14
0.19
14.6
3.9
7.34
7.33
ph
0.03
19
145
14
119
1.19
0.18
1.3
1.3
35.04
27.62
iu/l
0.24
14
97
44
469
0.93
0.14
1.5
1.3
1.52
13.64
u/ml
3.15
20
186
17
153
1.12
0.11
1.4
1.4
—
28.31
—
0
14
11
125
0.87
0.10
1.0
1.1
—
—
—
0
0
6
55
1.09
0.09
1.0
1.2
—
—
—
0
0
6
58
1.04
0.08
1.0
1.2
—
—
—
0
0
6
58
1.04
0.08
1.0
1.2
—
—
—
0
0
7
85
0.82
0.07
16.9
10.0
—
—
—
0
0
8
95
0.84
0.07
1.1
1.1
—
—
—
0
0
19
184
1.04
0.00
1.4
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
12.7
—
1055.33
—
0
9
0
8
0.00
-0.00
0.0
1.3
—
166.94
—
0
8
6
60
1.00
-0.00
1.0
1.2
—
—
—
0
0
5
59
0.84
-0.00
1.2
1.5
224.60
310.71
mu/l
—
5
52
0
5
0.00
-0.00
0.0
1.6
—
64.20
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.0
—
124.00
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
52
0.96
-0.00
1.2
1.3
11.82
12.98
u/l
—
5
39
0
5
0.00
-0.00
0.0
1.0
—
0.01
—
0
5
6
59
1.02
-0.00
1.0
1.2
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: Q17_CYSTIC_DISEASE_OF_LIVER – Cystic disease of liver

GWS hits: 12

This endpoint is excluded (different definition than used in FinnGen).